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 1 1. Introduction 
Figure 1. Gross anatomy of the eye ball and detailed cross-section of the human retina. A. The retina lines the back of 
the eye ball. B. Stained cross-section of the retina highlighting the different layers of the retina. RPE: retinal pigment 
epithelium, OS: outer segment, IS: inner segment, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear 
layer, IPL: inner plexiform layer, GCL: ganglion cell layer. C. Schematic overview of the organization of the retinal cells. R: 
rod, C: cones, H: horizontal cells, B: bipolar cells, A: amacrine cells, M: Müller cells, G: ganglion cell. Eye ball adapted from: 
http://sparemed.blogspot.de/2011/05/good-vs-bad-eyeball.html Retinal cross section modified from: 
http://pathology.wustl.edu/research/corbolab/projects.htm Schematic diagram of retinal cells adapted from Sung and 
Chuang, 2010 
1. Introduction 
1.1 Structure and Function of the Mammalian Retina 
The eye is the optical camera of the body which transmits and focuses light onto a complex highly-
structured neuronal tissue called the retina. The retina is located in the proximal segment of the 
eye and is the first station of the neuronal visual system (Fig 1A). The mammalian retina allows for 
the perception of color, shape and motion through complex signaling pathways which are 
ultimately amplified and extracted before being transmitted to the midbrain and thalamus via the 
optic nerves. Signal processing is carried out by five main classes of retinal cells which are 
segregated into alternate, anatomically distinctive layers (Fig 1B): photoreceptors, bipolar cells, 
amacrine cells, horizontal cells and ganglion cells (Fig 1C) (Sung and Chuang, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visual perception begins when light crosses the retina, which is approximately 0.2mm in thickness, 
and reaches the light-sensitive photoreceptor cells (Yau and Hardie, 2009). The retina contains 
two type of photoreceptor cells: rods and cones. In humans, the cone-photoreceptors are 
A B C 
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specialized in day- and color vision and enriched in fovea, whereas rod photoreceptors mediate 
vision in dim light and are located predominantly in peripheral areas of the retina. The human 
retina contains approximately 110 million rod- and  6 million cone-photoreceptors (Klinke and 
Toth, 2003). The photoreceptors are juxtaposed to the outermost layer of the retinal pigment 
epithelium (RPE) which is known to play a critical role in their regeneration. The RPE is 
responsible for the maintenance of retinal homeostasis, the formation of the outer blood‐retinal 
barrier and absorption of scattered or unabsorbed light. RPE cells also phagocytose membranous 
discs which are shed by photoreceptor outer segments (Dunn et al., 1996), recycle the light 
sensitive pigment rhodopsin and provide nutrients to the photoreceptors. The nuclei of the 
photoreceptors constitute the tightly packed outer nuclear layer (ONL) which are connected to the 
outer segments (OS) by the connecting cilium (Horst et al., 1990). Visual perception begins when 
the chromophore conjugated with opsin, absorbs a photon in the OS of a photoreceptor. The 
photo‐excited visual pigment initiates a signal transduction cascade which leads to the closure of 
cation channels and results in a hyperpolarisation of the cell membrane. This photo-transmission 
is forwarded to inner retinal cells such as the horizontal or bipolar cells via synapses in the outer 
plexiform layer (OPL). The cell bodies of the inner retinal cells are found in the inner nuclear layer 
(INL). Signals from the inner retinal cells are further relayed to the ganglion cells in the ganglion 
cell layer (GCL) via synpases found in the inner plexiform layer (IPL) (Sung and Chuang, 2010). 
Amacrine cells in the INL laterally modify signals from the horizontal cells to the ganglion cells, 
whose axons build the optic nerve which further transmits information to the midbrain (Masland, 
1988). Between the stratified layers of the retina exist two other cell types which are important for 
the maintenance and health of the retina: the Müller glia cells and microglia cells.   
 
1.2 Müller Cells 
Astrocytes are macroglias which are found in the brain in various forms, with one form existing in 
the mammalian retina called Müller cells (Reichenbach and Bringmann, 2010). Müller cells are 
specialized radial glial cells which span the entire thickness of the retina in columns contacting all 
retinal neuronal somas and processes (Bringmann et al., 2006). This anatomical link is important 
for information processing as well as neuronal survival. Among many other roles, Müller cells 
maintain the structural stability of the retina, regulate extracellular homeostasis of relevant ions, 
remove metabolic waste and metabolize glucose to lactate which is preferentially taken up by 
photoreceptors as a fuel for their oxidative metabolism (Poitry-Yamate et al., 1995; Newman and 
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Reichenbach, 1996).  Müller cells can also modulate immune and inflammatory responses and 
buffer mechanical deformations of the retina tissue (Lu et al., 2006; Bringmann et al., 2009; 
Reichenbach and Bringmann, 2010). However, the main cell type which modulate immune and 
inflammatory responses are the microglia.   
 
1.3 Microglia cells 
In contrast to macroglia cells which arise from primitive neuroepithelium together with neurons, 
microglia originate from myeloid precursors in the yolk sac during very early embryonic 
development before the formation of the blood brain barrier (Ginhoux et al., 2010). Like 
macrophages, microglia are mononuclear phagocytes and act as the resident immune cells of the 
central nervous system (CNS) (Kreutzberg, 1996). They make up 10% of total glial population in 
the CNS, are found ubiquitously and serve as sensors and executers of innate immunity within the 
CNS (Vaughan and Peters, 1974; Graeber and Streit, 2001).  
 
1.3.1 Microglia in the CNS and Retina 
Microglia cells were first described by Del Rio Hortega in 1919 as unique cells in the CNS with an 
elongated soma bearing processes extending from both poles of the cell (Del Rio Hortega, 1919). 
This phenotype is termed as ramified microglia. In this form, microglia are able to scan the 
environment using their processes allowing them to quickly identify changes or injuries in tissues 
(Raivich, 2005). Moreover, the highly motile microglial ramifications have been shown to 
continuously scan the CNS microenvironment with estimates that the complete brain parenchyma 
is monitored every few hours (Davalos et al., 2005; Nimmerjahn et al., 2005). Depending on their 
location in the CNS, microglia can have major morphological differences with regard to the size and 
orientation of their ramifications. The density of microglial cells also seems to be determined by 
region-specific cues. Such heterogeneity of microglia density and morphology might be linked to 
functional heterogeneity of microglia (Davoust et al., 2008). In the adult retina, microglia are 
normally found in the OPL and IPL  (Hume and Gordon, 1983) at the margin adjacent to the nuclear 
layers (Ebert et al., 2009; Karlstetter et al., 2010). From their location in the brain and retina, 
microglia can assess the homeostatic state of the tissue and carry out their functions.  
 
 4 1. Introduction 
1.3.2 Function of the Microglia Cells 
Microglia cells exert many physiological functions in the developing and adult CNS. These include 
the induction of apoptosis in specific subpopulations of developing neurons, the control of 
synaptogenesis, the synthesis of neurotrophic factors and the regulation of synaptic transmissions 
(Elkabes et al., 1996; Marin-Teva et al., 2004; Roumier et al., 2004; Coull et al., 2005). In order to 
carry out their function to maximum efficiency, microglia exist individually and keep their distance 
from one another while covering their own surveillance territory. This microglia immune network 
is different from other neuroglia which have established syncytial networks (Graeber, 2010). It is 
therefore likely that microglia communicate using auto- and paracrine mechanisms (Liu et al., 
2009).  
 
Microglia also communicate with neurons which signal microglia about their status via use of 
different ligands, neurotransmitters and neurotrophins (Kettenmann et al., 1990; Biber et al., 
2007; Pocock and Kettenmann, 2007). Two characterized ligands, CD200 and CX3CL1 (CX3C 
chemokine ligand 1, also known as fractalkine) , which are found to be constitutively expressed on 
the neuronal membrane surface have their corresponding receptors, CD200R and CX3CR1, 
expressed on microglial surface (Hoek et al., 2000; Biber et al., 2006). Signals between 
aforementioned ligands and receptors provide suppressive signals to microglia, preventing 
harmful activation as well as maintenance of homeostatic state (Carter and Dick, 2004; Cardona et 
al., 2006). Furthermore, CD200 and CX3CL1 stimulate microglia migration and protrusion 
movements, controlling surveillance frequency and vigilance in healthy tissues (Carter and Dick, 
2004). However, upon detection of injury or subtle alterations in their microenvironment, such as 
imbalances in ion homeostasis, microglia cells undergo morphological changes and enter an 
'active' state (Kettenmann et al., 1990).  
 
1.3.3 Activation and Morphological Plasticity of Microglia Cells 
One of  the most remarkable features of microglia is their high level of morphological and 
functional plasticity in response to activating stimuli. Under a number of pathological conditions, 
ramified microglia will activate and undergo a graded morphological transformation resulting in 
shorter, thicker processes and larger soma size (Kreutzberg, 1996). By the end of such a process, 
fully activated microglia, also called reactive microglia, harbor a similar morphology to activated 
macrophages (Fig 2). Microglia become more motile and actively move to site of injury as well as 
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Figure 2.  Microglia activation occurs in a graded manner. On the left: Ramified microglia are thin with protrusion extending 
from both poles of the cell. Upon alterations in the microenvironment, microglia undergo graded morphological changes including  
thicker somas, shorter protrusions, smaller cell size, rounded amoeboid cell shape with short thick protrusions and finally a fully 
phagocytic activated cell. Adapted from Kreutzberg, 1996. 
increase in local density, either by in situ proliferation or recruitment of myeloid cells from the 
blood stream. This results in a greater defense system of the tissue which can protect and restore 
tissue homeostasis (Xu et al., 2007; Soulet and Rivest, 2008; Graeber, 2010).  
 
 
 
 
 
 
 
 
 
 
Activated microglia are found to exert functions commonly assigned to all tissue-resident 
macrophages under inflammatory conditions. These include notably phagocytosis, antigen 
presentation and secretion of pro-inflammatory cytokines such as interleukin  (IL)-6 , IL-1 or 
tumor necrosis factor α (TNF-α), as well as reactive oxygen intermediates and nitric oxide (Banati 
et al., 1993; Bauer et al., 1994; Minghetti and Levi, 1998; Perry, 1998). In addition, microglia up-
regulate cell surface molecules including major histocompatibility markers (MHC class I and II) 
F4/80, complement receptor 3 (CD11b/CD18, OX42) and Griffonia simplicifolia isolectin B4 
(Gordon et al., 1988; Perry, 1998; Langmann, 2007a; Lynch, 2009). These markers are classical 
microglia markers used to detect microglia by immunohistochemistry and immunofluorescence-
staining procedures (Kreutzberg, 1996; Streit et al., 1999). The magnitude of microglial activation 
is influenced by the type and duration of the stimulus, the current CNS microenvironment and 
exposure to prior and existing stimuli (Schwartz et al., 2006; Perry et al., 2007; Ransohoff and 
Perry, 2009).  
 
The type of stimulus which activates microglia is very important. In response to certain cytokines 
such as interferon-γ (IFNγ) and tumor necrosis factor-R (TNFR) or after recognition of pathogen-
associated molecular patterns (PAMPs), microglia enter a 'classically' activated state normally 
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associated with strong immune defense (Laskin, 2009). In contrast, interleukin-10 (IL-10) or 
transforming growth factor-β (TGFβ) trigger 'alternatively' activated microglia which is associated 
with resolution of inflammation through phagocytosis of apoptotic neutrophils, reduced 
production of pro-inflammatory cytokines, and increased expression of mediators important in 
tissue remodeling, angiogenesis, and wound repair (Duffield, 2003; Van Ginderachter et al., 2006).  
 
Microglia activation occurs very early in response to injury, often preceding reactions of any other 
cell type (Gehrmann et al., 1995). Time-lapse in vivo imaging have shown that microglia appear 
minutes following injury, polarizing their processes toward the site of injury (Nimmerjahn et al., 
2005). Based on these studies as well as many others, microglial response to injury is generally 
thought to constitute the initial step of a generalized inflammatory response. Once the cause of 
stimulation has been removed, signals from neurons as well as the microenvironment will 
efficiently regulate neuroimmune response allowing the tissue to return to homeostatic state. This 
is in part regulated by the balance of 'classically' and 'alternatively' activated microglia. However, 
these neuromodulatory mechanisms may become deficient and/or dysregulated under excessive 
or prolonged inflammatory stimulation induced by disease and injury. In such cases, the microglial 
function which was initially important for host defense and neuroprotection, can have detrimental 
and neurotoxic effects (Block et al., 2007). It is now recognized that overly active microglia, 
normally of the 'classically' active class,  are associated with the pathogenesis of several 
neurodegenerative disorders including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), 
Parkinson’s disease and several retinal degenerative diseases (Boillee et al., 2006; Kim and Joh, 
2006; El Khoury et al., 2007).  
 
1.4 Inherited Diseases of the Eye 
Inherited retinal dystrophies are a heterogeneous group of disorders where an underlying 
inherited gene defect leads to impaired retinal function. They can be classified according to mode 
of inheritance, site of retinal dysfunction, age of onset, associated systemic syndromes or the 
underlying gene defect (Sundaram et al., 2012). To date, the Retnet (Retinal Information Network) 
database lists 232 genes which lead to retinal disease (https://sph.uth.edu/retnet/home.htm).  
Age-related Macular Degeneration (AMD), is the leading cause of vision loss in industrialized 
countries and is caused by genetic predisposition as well as environmental factors. Achromatopsia 
and Retinitis Pigmentosa (RP) together define a large class of monogenic diseases that affect vision 
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in humans, caused by a wide variety of mutations that disrupt visual transduction and 
photoreceptor maintenance. Due to the high oxygen consumption that is required for retinal light 
absorption, photoreceptors in particular, are greatly susceptible to injury and perturbations often 
resulting in cell death. In most cases, loss of vision is usually caused by photoreceptor loss which 
occurs though apoptotic mechanisms and/or non-apoptotic mediated cell death (Portera-Cailliau 
et al., 1994; Sancho-Pelluz et al., 2008).  
 
 In the mouse model of X-linked juvenile retinoschisis, Retinoschisis-deficient (Rs1h-/Y) mice 
develop massive photoreceptor degeneration very early in postnatal development, accompanied 
by splitting or schisis of retinal layers (Weber et al., 2002; Ebert et al., 2009). The rd1 (retinal 
degeneration) mouse model, which is a relevant RP model, has early rod photoreceptor 
degeneration starting at postnatal day 10 which has been attributed to apoptotic mechanisms 
(Chang et al., 1993) as well oxidative stress (Sanz et al., 2007). Photoreceptor cell death due to 
apoptosis and oxidative stress has also been reported in AMD animal models as well as patients 
(Curcio et al., 1996; Winkler et al., 1999; Dunaief et al., 2002). However, recent studies in AMD, 
Rs1h-/Y and rd1 mouse models now show significant induction of inflammatory markers as well as 
activation of microglial and Müller cells, which also play a major role in retinal disease progression 
and degeneration (Gupta et al., 2003; Patel and Chan, 2008; Ding et al., 2009; Ebert et al., 2009). 
 
1.4.1 Microglia in Retinal Degeneration 
Microglia activation has also been shown to contribute to retinal degeneration in a number of 
studies (Langmann, 2007).  Both genetic or retinal dystrophies caused by external factors  usually 
harbor active phagocytic microglia at lesion sites/site of cell loss. Numerous studies have shown 
that microglial activation is not simply a side-effect of heredity photoreceptor dystrophies, but an 
active contributor to retinal degeneration (Thanos, 1991; Schuetz and Thanos, 2004; Zeiss and 
Johnson, 2004; Karlstetter et al., 2010).  
 
Studies done on the aforementioned retinoschisis, Rs1h-/Y, mice using DNA-microarray analyses, 
identified several transcripts from activated microglia cells preceding gene expression patterns 
related to apoptosis (Gehrig et al., 2007). Furthermore, microglial transformation from ramified to 
an ameoboid phagoctyic morphology coincided with cell death (Ebert et al., 2009). This suggests 
early microglial activation as a key event preceding/triggering photoreceptor death (Gehrig et al., 
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2007; Langmann, 2007). Increased expression of the microglia-activating chemokines MCP-1, 
MCP-3, as well as high levels of microglia-secreted TNFα were also observed in the retina of Rd 
mice. These observations coincided with prominent microglial migration into the ONL well before 
photoreceptor apoptosis (Zeiss et al., 2004; Zeng et al., 2005). Diseased retinas from human AMD 
and RP patients have also revealed the presence of activated microglia in the ONL, bearing 
phagocytised fragments from dead photoreceptors (Gupta et al., 2003). Studies done by Joly et al. 
could show both resident and bone-derived macrophages co-operating to remove apoptotic 
photoreceptors in blue-light injured mouse retinas, indicating recruitment of peripheral 
macrophages (Joly et al., 2009).  In the retinal microenvironment, recruited macrophages 
transform phenotypically into microglia-like cells and actively contribute to the inflammatory 
processes (Kaneko et al., 2008). These studies, among many others, imply early microglial 
activation as an active cause or additive effect of retinal degeneration.  However, the molecular 
mechanism of microglial activation and whether the functional consequences are destined to be 
detrimental or protective is unclear. It is important to note, that morphology does not accurately 
reflect the activation state of microglia. As mentioned above, different patterns of activation lead to 
distinct functional profiles, which may be associated with the common 'activated' morphology 
(Schwartz et al., 2006).  Nonetheless, in most diseases, there is a greater presence of neurotoxic 
microglia compared to the neuroprotective counterpart. 
 
1.4.2 Müller Cells in Retinal Degeneration  
Like microglia cells, Müller cells can also become 'activated' or 'reactive' in response to 
pathological alterations in the retina. This reaction, also known as Müller cell gliosis, is one part of 
a complex retinal response to pathogens which also includes inflammatory and immune responses. 
Reactive gliosis may be a cellular attempt to protect retinal tissue from further damage and 
promote tissue repair by releasing neurotropic factors and antioxidants (Schutte and Werner, 
1998). However, some factors which are released by Müller cells, such as vascular endothelial 
growth factor (VEGF), may at first have neuroprotective effects but later contribute to disease 
progression by inducing vascular leakage and neovascularozation (Miller et al., 1994; Yasuhara et 
al., 2004). Notably, Müller cells up-regulate glial intermediate filaments vimentin and glial fibrillary 
acidic protein (GFAP). These are sensitive and non-specific responses to retinal disease and/or 
injury, which are used as early indicators of retinal stress (Bignami and Dahl, 1979; Lewis and 
Fisher, 2003). These intermediates are also expressed by some astrocytes when pathogens or 
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insults occur in the brain. Along with GFAP and vimentin, inflammatory factors such as monocyte 
chemoattractant protein-1 are also up-regulated and can recruit microglia to site of injury 
(Nakazawa et al., 2006; Nakazawa et al., 2007b). Microglia, in turn, release oxygen free radicals and 
cytokines which contribute to photoreceptor apoptosis. A study using GFAP- and vimentin-
deficient mice with induced retinal detachment showed reduced microglial infiltration and 
decreased photoreceptor apoptosis (Nakazawa et al., 2007a). Similar results were also found after 
experimental blue-light retinal injury in GFAP- and vimentin- deficient rats (Iandiev et al., 2008).  
In severe cases of gliosis, proliferation of Müller cells contributes to neuronal cell death by 
impairing tissue homeostasis, which in turn increases the susceptibility of neurons to stressful 
stimuli in diseased retinas (Fisher et al., 1991). 
 
1.5 Neuronal Ceroid Lipofuscinosis (NCL) 
One particular disease which is an inherited degeneration of the retina and CNS is Neuronal Ceroid 
Lipofuscinosis (NCL), First identified in 1826 by Dr. Otto Christian Stengel, NCL is defined as a 
progressive degenerative disease of the brain and most cases, retina, in association with 
intracellular accumulation of storage material known as ceroid lipofuscin.  Despite over 100 years 
of research and the vast accumulation of knowledge on genes, proteins and pathways, there is no 
treatment for NCL (Haltia, 2003, 2006; Haltia and Goebel, 2012).  
 
1.5.1 Characteristics of NCL 
Collectively, the NCLs are the most common cause of progressive encephalopathies in children 
(Haltia, 2006; Kollmann et al., 2013). Incidence is estimated to be 1:25 000-50 000 in the USA 
(according to The National Institute of Neurological Disorders and Stroke) and ranging between 
1:25 000 and 1:200 000 in European countries (e.g. Norway, Germany and Italy)(Williams, 2011). 
Up to date, almost 400 causative mutations have been reported in 13 CLN genes (Table 1) (NCL 
Mutation and Patient Database, http://www.ucl.ac.uk/ncl /mutation.shtml). Symptoms of NCL 
disease include epileptic seizures, ataxia, mental and motor regression, myoclonus and/or visual 
failure (Warrier et al., 2013).  Although there are various kinds of NCL, they do share some 
common traits: 1) the accumulation of  auto-fluorescent, electrondense granules in most nerve 
cells and, to a lesser extent, in many other cell types, 2) varying degrees of cerebral/cerebellar 
neurodegeneration (Haltia and Grobel, 2012). It is now becoming evident that severe up regulation 
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inflammatory processes, microglia and astrocytes are also part of the NCL pathogenesis. Although 
the relative timing and rate of disease progression differs between different forms of NCL, all end 
inevitably with the premature death of the affected individual. 
 
The NCLs are subdivided into categories based on molecular genetic findings, age of onset and the 
ultra structure appearance of storage material (Table 1). The NCLs are normally classified as 
congential, infantile, late-infantile, juvenile and adult form (Haltia and Goebel, 2012). NCL 
diagnosis is based on genetic or enzymatic tests from a blood, skin biopsy or saliva samples. 
Prerequisite for NCL diagnosis is the existence of intracellular storage material, which can be 
studied using electron microscopy on lymphocytes from skin/rectal biopsies. Monitoring 
electroencephalogram (EEG), electroretinogram (ERG), measuring the visual and/or 
somatosensory evoked potentials (VEPs, SEPs) or performing neuroradiological analyses may also 
assist the diagnosis of certain forms of NCL (Kousi et al., 2012). 
 
1.5.2 NCL as a Lysosomal Storage Disorder 
The NCLs are considered as inherited lysosomal storage disorders (LSDs). Lysosomes are 
primarily characterized as acidic organelles which contain the primary hydrolysis machinery of the 
cell required for the degradation of proteins, lipids, and carbohydrates, and whole organelles. 
Lysosomes are globular or tubular-shaped vacuoles with variable electron-dense constituents. 
Their lumen is acidic (pH 4.5 – 5) and contains membrane sheets and intraluminal vesicles. LSDs 
are mostly recessively inherited, fatal diseases characterized by a progressive accumulation of un-
degraded metabolite(s) in the lysosome but also in other intracellular and extracellular locations. 
Several types of macromolecules have been identified to be stored in LSDs, including sphingolipids, 
mucopolysaccharides, oligosaccharides, glycoproteins, lipids, sulfatides, and specific proteins and 
amino acids (Futerman and van Meer, 2004; Ballabio and Gieselmann, 2009). Most of the LSDs are 
due to mutations in soluble lysosomal hydrolases but can be caused by a multitude of mutations 
which cause functional impairment (Ruivo et al., 2009).  
 
Most of the NCL proteins are, in fact, present in the lysosomes where ceroid lipopigments 
accumulate. Lipofuscin and ceroid are fluorescent storage material largely composed of protein, 
which in most NCLs is the subunit c of mitochondrial F1-F0-ATP synthase. In certain subtypes, 
mainly in infantile and congenital disease, the main protein components of the storage material are 
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sphingolipid activator proteins (saposins) A and D. However, the role NCL proteins play in 
lysosomes or else-where in the cells as well as NCL disease mechanism is largely unknown (Haltia, 
2003; Seehafer and Pearce, 2006).  
 
 
 
Disease Onset Gene Affected Function Location Storage 
component 
First identification 
CLN1 Infancy Palmitoyl protein 
thioesterase 1 (PPT1) 
Palmitoyl- 
thioesterase 
Lysosome Saposin A/D (Vesa et al., 1995) 
CLN2 Late-infancy Tripeptidyl peptidase 1 
(TPP1) 
Serine protease Lysosome subunit c (Sleat et al., 1997) 
CLN3 Juvenile CLN3 Unknown Lysosome 
Endosome 
subunit c (Consortium, 1995) 
CLN4 Adulthood Cysteine-string protein 
alpha (CSPα), DNAJC5 
Chaperone Plasma 
Membrane 
Saposin A/D (Noskova et al., 
2011) 
CLN5 Late-infancy CLN5 Unknown Lysosome subunit c (Savukoski et al., 
1998) 
CLN6 Late-infancy CLN6 Unknown ER subunit c (Wheeler et al., 
2002) 
CLN7 Late-infancy MFSD8 Unknown Lysosome n.d. (Siintola et al., 
2007) 
CLN8 Late-infancy CLN8 Unknown ER-Golgi  
intermediate 
compartment 
subunit c (Ranta et al., 1999) 
CLN 10 Congenital Cathepsin D (CTSD) Aspartyl 
endopeptidase 
Lysosome subunit c (Siintola et al., 2006; 
Steinfeld et al., 
2006) 
CLN 11 Adult Progranulin GRN Unknown Extracellular Saposin D (Smith et al., 2012) 
CLN 12 Juvenile ATP13A2 Unknown Lysosome n.d. (Bras et al., 2012) 
CLN 13 Adult Cathepsin F (CTSF) Cysteine 
protease 
Lysosome n.d. (Smith et al., 2013) 
CLN14 Infantile Potassium channel 
tetramerization 
domain-containing protein 
7 (KCTD7) 
Unknown Cytosolic n.d. (Staropoli et al., 
2012) 
 
 
1.5.3 Characteristics of CLN3 Mutations 
Mutations in the CLN3 gene result in juvenile neuronal ceroid lipofuscinosis (JNCL, Batten disease, 
OMIM#204200). World wide, JNCL represents the most common form of NCL. Currently, 57 
Table 1: The neuronal ceroid lipofuscinosis classified according to clinical onset, affected gene, protein 
function, protein location, storage component and first identification of causative gene 
Table 1: List of CLN genes which carry NCL causing mutations. Abbreviations. CLN1 ect: Ceroid lipofuscinosis 1 ect.; n.d.: not described. 
References: Kollmann et al., 2013, Warrier et al., 2013, NCL Mutation and Patient Database, http://www.ucl.ac.uk/ncl/mutation.shtml 
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mutations have been characterized in the CLN3 gene (NCL Mutation and Patient Database). The 
most common mutation is a 1.02 kb deletion of exon 7 and 8 which results in a severely truncated 
protein with residual function, (Kitzmuller et al., 2008). JNCL usually begins with visual failure due 
to retinal degeneration at 5–10 years of age. Mental retardation develops slowly and is followed by 
epilepsy and deterioration of motor skills. Juvenile NCL is also connected to different psychiatric 
symptoms like aggressiveness, depression and sleep problems. The clinical course is largely 
variable and the death occurs between 20-30 years of age. At autopsy, the cerebral cortex is 
narrowed and the weight of the brain is decreased (Haltia, 2003). Unfortunately, because 
neurological symptoms often begin years after occurrence of visual problems, JNCL patients are 
considered as otherwise normal children with vision loss often mistaken as a maculopathies 
(Collins et al., 2006). This significantly delays accurate patient diagnosis.  
 
The CLN3 gene is located on chromosome 16p12 and encodes a hyrophobic transmember protein 
of 438 amino acids called battenin. CLN3 is normally detected in endosomal/lysosomal structures 
in neurons and gets transported to synaptosomes (Kyttala et al., 2004). CLN3 functions are 
postulated to include lysosomal acidification, membrane fusion, vesicular transport, autophagy 
and proteolipid modification (Jalanko and Braulke, 2009; Kollmann et al., 2013). However, the 
precise function of CLN3 remains elusive, making it difficult to evaluate the impact of the 
mutations on the resultant peptides (Kollmann et al., 2013).  
 
1.5.4 Characteristics of CLN6 Mutations 
Mutations in the CLN6 gene cause a variant late infantile NCL (vLINCL; OMIM#601780) (Gao et al., 
2002; Wheeler et al., 2002), as well as an adult form termed Kufs type A disease (OMIM#204300) 
(Arsov et al., 2011). At present, 68 disease-causing mutations have been described (NCL Mutation 
and Patient Database). The most common mutation, which leads to vLINCL, is a 1-bp insertion in 
exon 4 (c.316insC) causing a frame shift mutation and premature stop codon resulting in a 
truncated protein (Kurze et al., 2010). The age of onset for vLINCL caused by CLN6 mutations is 
between 18 months and 8 years of age with the most common presenting features being motor 
delay, dysarthria and ataxia. Addition symptoms include mental regression, speech impairments 
and in approximately 50 percent of cases seizures and loss of vision (Mole et al., 2005; Moore et al., 
2008). Disease progression is rather variable with death occurring between 5 to 30 years of age 
(Pena et al., 2001; Jalanko and Braulke, 2009).   
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The CLN6 gene on chromosome 15q23 encodes an endoplasmatic reticulum (ER) resident 
transmembrane protein 331 amino acids long, named linclin or CLN6p. CLN6 is conserved across 
vertebrates showing no sequence homology with other proteins. Mutations in CLN6 do not have an 
impact on normal distribution or its ability to dimerize (Mole et al., 2004; Kurze et al., 2010).  
Instead, is it postulated that mutations exert their pathogenic effect on the stability and function of 
mutant polypeptides, possibly reducing rate of synthesis and stability compared to wild type 
peptides (Kurze et al., 2010). CLN6p has also been shown to interacts with collapsin response 
mediator protein-2 (CRMP-2) which controls axon growth (Benedict et al., 2009). Recent studies 
have now shown the CLN6nclf mutation also results in disruption of the autophagy-lysosome 
degradation pathway suggesting the CLN6 protein may be important for fusing autophagosomes 
and lysosomes (Thelen et al., 2012).  
 
1.5.5 Animal Models of CLN3 and CLN6 
Animal models exist for all subtypes of NCL disorders (NCL Animal Models Database 
http://www.ucl.ac.uk/ncl/animal.shtml). These are either spontaneously occurring or engineered 
and they have been described in organisms ranging from the single celled yeast to larger animal 
models such as sheep and dog (Cooper et al., 2006).  
 
Orthologs of CLN3 can be found across many species and have been studied in Drosophila 
Melanogastor, C. elegans, unicellular yeasts Saccharomyces cerevisiae and Schizosaccharomyces 
pombe and mouse models.  Pioneering work done on CLN3-deficiency yeast models, btn1, 
significantly contributed to understanding CLN3 function (Pearce and Sherman, 1997; Gachet et al., 
2005; Rakheja et al., 2008). In order to better understand CLN3 mutations in mammals, four mouse 
models of JNCL have been established and characterized to varying degrees (Cooper, 2006). All 
mouse models display recessive features of JNCL including accumulation of ceroid lipofuscin, brain 
gliosis, neurological dysfunction and neurodegeneration. The Cln3Δex7/8 knock-in mouse represents 
the only genetically accurate JNCL mouse model, and therefore may be most predictive of the 
earliest molecular and cellular consequences of CLN3 mutation in JNCL (Cotman et al., 2002) and 
the only one which has been fully phenotyped (Strapoli et al., 2012).   
 
In contrast to the engineered CLN3 models, CLN6 disease occurs naturally in mouse, sheep and dog 
(Jolly et al., 1989; Gao et al., 2002; Wheeler et al., 2002; Tammen et al., 2006; Katz et al., 2011). The 
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CLN6 mutant mouse model, Cln6nclf, possesses an identical mutation (c.307insC) to the most 
common CLN6 human mutation mentioned. The course of the Cln6nclf neurodegenerative 
phenotype also recapitulates the human CLN6 disease with homozygous mice developing 
progressive retinal atrophy, cerebral atrophy, spastic limb paresis starting at eight months, 
paralysis and premature death at one year of age (Bronson et al., 1998; Wheeler et al., 2002; Sharp 
et al., 2003; Siintola et al., 2005).   
 
1.5.6 Retinal Degeneration in NCL 
Vision loss is typically evident in patients with NCL at early age making ophthalmologists often the 
first specialists seen by patients (Birch, 1999). Retinas of NCL patients are normally affected by 
two different pathological processes, 1- accumulation of disease specific lipopigments in the 
neuronal perikarya and retinal pigment epithelium cells, 2- progressive degeneration of the 
neuronal elements, commencing at the photoreceptors. At autopsy, patients eyes normally exhibit 
severe atrophy of the entire retina (Goebel, 1992).  
 
Many NCL models also exhibit varying levels of retinal degeneration and vision problems. Among 
them are mutant forms of CLN1, CLN3, CLN5, CLN6, CLN8 and CLN10, which have been studied 
using electroretinograms (ERGs).  ERGs are a good method for measuring retinal cell function and 
can be used on both patients and animals. Briefly, ERGs measure electrical responses from the 
retina upon light stimulation which are recorded as waves; the a-wave which is the first negative 
component, indicating the general health of the photoreceptors, followed by the b-wave which is 
has a large positive amplitude, reflecting the health of the inner layers of the retina (Creel, 2013).   
 
Retinal studies in the Cln8mnd mouse showed reduced ERG amplitudes in both the a- and b-wave 
starting at two months until the signals became barely recordable by five months of age. These 
functional measurements were accompanied by obvious morphological retinal degeneration which 
appeared four months before motor paralysis starts (Chang et al., 2002).  ERG studies done on 
Cln3Δex7-8 mice past nine months of age showed a reduction in the b-wave whilst maintaining a 
relatively normal a-wave function, indicating that the inner retina is the most affected region 
(Strapoli et al., 2011). Ppt1-/- (CLN1) mice, a model for the infantile form of human NCL, showed 
only moderate changes in retinal morphology and reduction in the b-wave amplitudes (Lei et al., 
2006). Retinal degeneration in Cln6nclf mice have also been studied, showing retinal degeneration 
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starting at four months of age resulting in loss of the ONL by nine months of age (Bronson et al., 
1998).    
 
1.5.7 Glial Activation in NCL 
Neuropathology, genome wide expression profiling and cellular analyses in several NCL mouse 
models have firmly established hyperactivity of the immune system prior to neurodegenerative 
events as a potential early disease mechanism (Elshatory et al., 2003; Chattopadhyay et al., 2004; 
Kopra et al., 2004; Jalanko et al., 2005; Jalanko et al., 2006). Autopsy material from patients with 
different forms of NCL also show consistent and regionally specific pattern of astrocytosis and 
microglial activation in the brain (Tyynela et al., 2004).  
 
Early prominent activation of astrocytes and microglia were first observed in CLN6-deficient South 
Hampshire sheep (Oswald et al., 2005). Activated astrocytes appeared in developing white matter 
40–20 days before birth and astrocytic activation within the gray matter 20 days before birth. 
Clusters of activated microglia were detected in upper cortical gray matter layers 12 days after 
birth defining regions most vulnerable to neurodegeneration, which starts at two months of age 
(Oswald et al., 2005). Cln6nclf mouse brains also show localized reactive astrocytes and microglia, 
most prominent in the thalamocortical system, starting between five to six months of age (Bronson 
et al., 1998; Thelen et al., 2012).  
 
Increased reactive astrocytes is the fist histopathological change observed in specific regions of the 
Ppt1-/- mouse brain, starting at 3 months of age. These regions also suffer significant neuronal loss 
subsequent to gliosis (Kielar et al., 2007; Macauley et al., 2009). However, when these mice were 
crossed with GFAP-/- Vimentin-/- mice, resulting in loss of astrocytes in the brain, it resulted in an 
accelerate brain degeneration (Macauley et al., 2011). These experiments highlight the protective 
and deleterious effects  gliosis can have. Moreover, studies done by Groh et al., in which 
lymphocytes were inactivated in Ppt1-/- mice, showed a substantial disease attenuation, 
unequivocally defining immune cells as pathogenic mediators in infantile NCL (Groh et al., 2013).  
 
Studies done on Cln3−/− and Cln3Δex7-8 mice also showed selective loss of inhibitory interneurons 
and early low level glial activation preceding neuron loss most pronounce in the thalamocortical 
system  (Pontikis et al., 2004; Pontikis et al., 2005). 
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1.6 Glial Attenuation with Natural Compounds 
The presence of glial activation in numerous degenerative diseases has resulted in the search for 
therapeutic interventions which can modulate astrocyte and microglia activity while reducing 
inflammatory marker expression and simultaneously support neuronal survival.  Therapeutic 
strategies include targeting ligands which activate microglia (Jin et al., 2007; Veiga et al., 2007), 
enhancing protective endogenous mechanisms (Zhu et al., 1999) and immuno-modulation with 
natural compounds (Ebert et al., 2009; Dirscherl et al., 2010; Karlstetter et al., 2011). 
 
1.6.1 Curucmin 
Curcumin ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), derived from 
the plant Curcuma longa, is a major constituent of tumeric which has been used as herbal medicine 
in India and China for centuries (Ammon and Wahl, 1991). Curcumin has been show to inhibit the 
defense program of microglia by diminishing the production of nitric oxide and secretion of pro-
inflammatory cytokines (Jung et al., 2006; Jin et al., 2007). It has also been shown to protect 
dopaminergic neurons against microglia-mediated neurotoxicity (He et al., 2010). Curcumin 
supplementation in a rat model of acute-light damage had functional and structural protection of 
photoreceptors along with decreased inflammatory gene expression (Mandal et al., 2009). 
Curcumin treated activated microglia become neuroprotective and can rescue neurons from 
apoptosis in vitro (Yang et al., 2008) as well as reduce microglial migration (Karlstetter et al., 
2011).  
 
1.6.2 Luteolin 
Luteolin (3’,4’,5,7-tetrahydroxyflavone) is a flavonoid abundant in parsley, green pepper, celery, 
and chamomile tea (Lopez-Lazaro, 2009). It has been shown to suppress pro-inflammatory 
cytokine IL-6 production in macrophages by blocking nuclear factor kappa B (NFkB) and activator 
protein 1 signaling pathways (Chen et al., 2007). Like curucmin, it has also been shown to inhibit 
production of nitric oxide (Hu and Kitts, 2004). Supplementation studies done on aged mice 
between 22-24 months of age showed reduced microglia activity in the hippocampus as well as 
reduced inflammatory marker expression (Jang et al., 2010). Luteolin treatment also attenuates 
microglial activation and induces a neuroprotective phenotype in vitro (Chen et al., 2008; Dirscherl 
et al., 2010). 
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1.6.3 DHA 
Docosahexaenoic acid (DHA, 22:6n-3), a polyunsaturated fatty acid enriched in fish oil also 
dampens microglial nitric oxide production (Antonietta Ajmone-Cat et al., 2012) and attenuates 
microglial reactivity in a mouse model of inherited retinal degeneration (Ebert et al., 2009). DHA is 
highly enriched in the retina and is a precursor for neuroprotectin D1, promoting the survival of 
photoreceptors and RPE cells (Mukherjee et al., 2007). DHA has also been shown to inhibit the 
synthesis of inflammatory products by microglia allowing better survival of neural progenitor cells 
(Antonietta Ajmone-Cat et al., 2012). Furthermore, it has been previously reported that patients 
with juvenile NCL have reduced DHA levels in plasma and cerebral cortex, which may contribute to 
retinal and brain degeneration (Kohlschutter et al., 1993b). 
 
1.7 Aim of the Thesis 
Despite all the studies done on glial activation in the NCL brain, the presence of glial activation in 
the retina  and whether it is the cause of retinal degeneration has not been studied. It is postulated 
that retinal glial activation in CLN mouse models represents an early event before the onset of 
overt neurodegenerative symptoms which leads to retinal dystrophy and blindness. Furthermore, 
therapeutic targeting of retinal glia cells and inflammatory processes could delay neuronal 
degeneration, hence improving symptoms. Results from immuno-modulation of the retina could be 
a basis to further evaluate the potential of immune-related therapies in the brain. 
 
The aim of this study was divided into three parts.  
 
1. Characterize the visual function and retinal degeneration of two NCL mouse models, 
Cln3Δex7-8  and Cln6nclf , using optokinietic and electroretinogram measurements, as well as 
histological assessment.  
 
2. Analysis retinal microglia and Müller cell activation in relation to progressive 
neurodegeneration using immunohistochemistry as well as glial and inflammatory marker 
gene expression.   
 
3. Select one mouse line with the most prominent glial activation, which best correlates to 
onset of retinal degeneration, and do supplementation studies with curcumin, luteolin and 
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DHA in order to attenuate inflammatory processes resulting in reduced retinal 
degeneration.  
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2. Materials 
All materials, software and machines used in this thesis were provided by the Institute of Human 
Genetics at the University Clinic Regensburg, unless otherwise specified.  
 
2.1 Mouse Models  
Table 2: Mouse models used in thesis studies 
Mouse Model Origin Mutation Genetic Background Reference 
Cln3
Δex7-8
 Charité Berlin, Dr. Klaus Ruther Knock-In C57BL/6N Cotmann et al., 2002 
Cln3
+/+
 Charité Berlin, Dr. Klaus Ruther  C57BL/6N  
Cln6
nclf
 Charité Berlin, Dr. Klaus Ruther c.316insC C57BL/6J Bronson et al., 1998 
Cln6
+/+
 Charité Berlin, Dr. Klaus Ruther  C57BL/6J  
Wild type Charles River (Sulzfeld, 
Germany)  
inbreed C57BL/6N  
Table 2: List of animals used in study, origin, mutation, genetic background and reference.  
 
2.2 Oligonucleotides for real-time RT-PCR 
Table 3: List of oligonucleotides (Metabion) and probes (Roche) used for quantitative real time 
RT-PCR.  
Gene Accession # Primer Sequence (5'-3') Probe  
ATPase  NM_016774  F 
R 
GGCACAATGCAGGAAAGG  
TCAGCAGGCACATAGATAGCC  
77 
Casp8  NM_009812  F 
R 
TGAACAATGAGATCCCCAAAT  
CAAAAATTTCAAGCAGGCTCA  
11 
Cd68  NM_009853  F 
R 
CTCTCTAAGGCTACAGGCTGCT  
TCACGGTTGCAAGAGAAACA  
27 
Cd95  NM_007987  F 
R 
AAACCAGACTTCTACTGCGATTCT  
GGGTTCCATGTTCACACGA  
76 
C1qa NM_007572.2 F 
R 
GGAGCATCCAGTTTGATCG 
CATCCCTGAGAGGTCTCCAT 
16 
Edn2  F 
R 
TGGCTTGACAAGGAATGTGT 
GCCGTAGGGAGCTGTCTGT 
29 
Egr1  NM_20157  
 
F 
R 
CCTTCCAGGGTCTGGAGAA  
ACTGAGTGGCGAAGGCTTTA  
3 
Gfap  
 
NM_010277  
 
F 
R 
ACAGACTTTCTCCAACCTCCAG  
CCTTCTGACACGGATTTGGT  
64 
Nclf NM_001033175.2 F 
R 
GGCGAAGAAGGTGAAGATGA 
AGAGCCACATGCCAGGAC 
104 
Tgfb1 NM_011577.1 F 
R 
TGGAGCAACATGTGGAACTC 
CAGCAGCCGGTTACCAAG 
72 
Tnfα  
 
 F 
R 
CTGTAGCCCACGTCGTAG  
TTGAGATCCATGCCGTTG  
25 
Table 3. Primer and probes for TaqMan assays 
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2.3 Enzymes 
Table 4: Overview of enzymes used in experiments 
Enzyme Use Firm, Article # 
Antartctic Phophatase Sequencing NEB, M02895 
DNAse I recombinant TUNEL-Assay  Roche; 04536282001  
Exonucleaase Sequencing USB, 70073 
House Taq-polymerase Mouse Genotyping Dr. Ulrike Friedrich (Institute for Human Genetic, Regensburg)  
Revert AidTM M-MuLV  
ReverseTranscritpase  
Reverse transcription Fermentas; EP0442  
Taq Polymerase  Mouse genotyping Genaxxon; M3454  
Taq Polymerase  PCR and sequencing Qiagen; 105476 
Table 4. Enzymes: use and firm of purchase 
 
2.4 Antibodies 
Tables 5.and 6: List of primary and secondary antibodies used 
Primary Antibody Species Dilution Firm, Article # 
F4/80 Rat monoclonal 1:600 Acris, BM4007S 
GFAP Rabbit, polyclonal 1:600 Sigma, G9269 
Iba1 Rabbit, polyclonal 1:500 Wako, 01-1974 
Table 5. Primary antibody, species, dilution and firm of purchase 
 
Secondary Antibody Species Dilution Firm, Article # 
Goat anti-Rat IgG Alexa Fluor 594  Rat 1:800 Invitrogen; A11007  
Goat anti-Rabbit IgG Alexa Fluor 488 Rabbit 1:1000 Invitrogen; A11008  
Table 6. Secondary antibody, species, dilution and firm of purchase 
 
2.4 Chemical and Kit System  
Table 7 and 8: List of chemicals and kit-systems used 
Chemical Use Firm, Article # 
30% H2O2  Different Merck, 1.07209  
Biozym LE Agarose  Agarose gel Biozym, 840004  
Boric Acid 1x TBE buffer Merck; 1.00165  
Bromophenol blue 10x-DNA loading buffer Sigma, B-6131  
BSA Immunohistochemistry, flat mounts Applichem, A6588  
Dako mounting medium Stained tissue preservation Dako, S3023 
DAPI  Immunohistochemistry Invitrogen, D1306  
dNTPs  Genotyping/ sequencing Genaxxon, M3018 - M3021  
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Chemical Use Firm, Article # 
EDTA  10x TBE buffer Merck, 1.08418.1000  
Eosin Y  HE stain Applichem, A0822  
Ethanol Different J.T. Baker, UN 1170  
Ethidium Bromide Agarose gel Applichem, A2273  
Glycerin  10x DNA loading buffer Applichem, A3561  
HCl Different Merck,1090571000  
Hematoxylin HE stain Sigma, HHS16  
Isopropanol Different Merck, 100995  
Ketamin 10% Mouse anaesthesia Dr. Thilo Spruss, head of aninal 
care, Regensburg University 
M-CSF  Cultivation of ex-vivo Microglia cells R & D, 216-MC/CF  
MgCl  15x Puffer  Merck, 1.05833  
Na2HPO  10x PBS buffer Merck, 106566  
NaCl  Different VWR, REF 27810.364  
NaN3  Immunohistochemistry, flat mounts Sigma; S-2002  
NaOH Different Merck; 1064981  
Nuclease Free water Different Promega; Cat. P1193  
 
Paraformaldehyde Immunohistochemistry, flat mounts Applichem; A3813  
Powdered skimmed milk Immunohistochemistry, flat mounts Roth, T145.3  
RNAse ZAP  RNA-isolation Sigma; R-2020  
SDS Different Roth,  CN30.3  
Sodium Acetate 10x DNA loading buffer  
Sodium Citrate TUNEL assay Merck, 1.06448  
Sucrose Kyro-embedding Merck; 1.07651  
Tris-HCl Different USB,123008  
Triton X-100  Flat mounts Sigma; X100  
Tween 20  Flat mounts Sigma; P1379  
Xylazin 2%  Mouse anaesthesia Dr. Thilo Spruss, head of aninal 
care, Regensburg University 
Xylencyanol  10x DNA loading buffer Sigma; X-4126  
Xylol  HE stain Roth, 9713.1  
β-mercaptoethanol RNA-isolation Merck; 1.07209  
Table 7. Chemicals: use and firm of purchase 
 
Kit-system Use Firm, Article # 
BigDye Terminator Sequencing Kit  Sequencing Applied Biosystems  
In Situ Cell Death Detection Kit, POD  TUNEL assay Roche; 11684817910  
RevertAidTM H Minus First Strand 
cDNA Synthesis Kit  
Reverse transcription Fermentas; K1632  
RNeasy Mini Kit  RNA isolation Qiagen; 74104  
TaqPCR Core Kit  PCR Qiagen; 201225  
RNA 6000 Nano LabChip Kit  RNA quality control Agilent Technologies; 5067-1511  
Table 8. Kit system: use and firm of purchase 
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2.5 Dietary Supplementation 
Table 9: Diet and supplements used for supplementation study 
Supplementation Purity % Firm 
EF-M diet (Control)  SSNIFF Spezialdiäten GmbH 
Curcumin 99 ChemHome, Shanghai Honghao Chemicals Co.,Ltd., Shanghai, China 
Luteolin 98 Hangzhou Skyherb Technologies. Co., Ltd., Zhejiang, China 
DHA (DHASCO-T)  Martek Biosciences Corporation, Columbia, MD, USA 
Table 9. Diet, supplements and firm of purchase 
 
2.6 Electroretinograms 
Table 10: Special materials needed for ERGs 
Material Firm 
Tropicamide eyedrops Mydriaticum Stulln Pharma 
Corneregel Bausch & Lomb 
Ganzfeld bowl Roland Consult, Ganzfeld QC450 SCX,  
Amplifier and recording unit Roland Consult, RETI-Port,  
Table 10: ERG materials and firm of purchase 
 
2.7 Buffers and Solutions 
Table 11: Lists of buffers and solution used 
Buffer/Solutions Composition Use Firm, Article # 
1 kb DNA ladder  Agarose gel Fermentas; SM0332  
10x Buffer S  15 mM MgCl2  Mouse genotyping Genaxxon; M3454  
10x DNA loading bubber 10 mM Tris-HCl (pH 7,5)  
5 mM Sodium Acetate  
2 mM EDTA  
10% Glycerin  
0,001% (w/v) Bromphenol blue  
0,001% (w/v) Xylencyanol  
Agarose gel  
10x PBS 1,5 M NaCl  
83 mM Na2HPO4  
17 mM H2PO4 (pH 7,4)  
 
Different  
10x TBE Buffer  1 M Tris  
1 M Boric Acid 
20mM EDTA (pH 7.5)  
Gel electrophoresis  
18% Sucrose 18% (w/v) Sucrose in sterile 
dH2O  
Cryo-preservation  
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Buffer/Solutions Composition Use Firm, Article # 
20% SDS Buffer  
 
20 g SDS in 100 ml H2O  Different  
2x TaqMan® MasterMix   TaqMan assay Applied Biosystems,  
4370074  
 
3% H2O2 Solution 3% (v/v) H2O2 in 1x PBS  TUNEL assay  
4% PFA-Lösung  4% (w/v) PFA in 1x PBS 
(pH 7,0  
Immunohistochemistry, flat 
mounts 
 
Agarose Gel 0,75-2% (w/v) Agarose in 
1x TBE-Buffer  
Agarose gel  
Alkaline lysis buffer 25mM NaOH 
0.2mM EDTA 
DNA isolation  
Antibody solution 2% BSA,  
0,02% NaN3  
0,1% Triton X-100 in 1x 
PBS  
Immunohistochemistry, flat 
mounts 
 
BLOTTO  1% Skimmed powdered 
milk  
0,01% Tween 20 in 1x 
PBS  
 
Immunohistochemistry, flat 
mounts 
 
DAB substrate  TUNNEL assay Roche,1718096  
Dako mounting medium  Immunohistochemistry, flat 
mounts 
Dako, S3023 
DAPI solution 0,1 μg/ml DAPI in 1x PBS  Immunohistochemistry  
Neutralizing buffer 40mM Tris-HCl (pH 5) DNA isolation  
Permeabilization buffer 25% Triton X-100  
25% Tween 20 in 1x PBS  
Flat mounts  
Permeabilization buffer 0,1% Triton X-100  
0,1% Natriumcitrat in 1x 
PBS  
TUNEL assay  
RNA Later   RNA isolation Ambion; AM7020  
Tissue-Tek OCT 
Compound 
 Tissue embedding Hartenstein, TTEK 
Table 11. Buffers and solutions: composition, use and firm of purchase 
 
 
 
2.8 Basic Materials 
Table 12: All basic materials needed for experiments 
Material Use Firm, Article # 
1 ml tips  RNA isolation  B & D Systems; REF 300013  
1,5 ml Cups  Different  Sarstedt; REF 72.706.400  
10 μl Filter tips  Different Biozym; 770020  
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Material Use Firm, Article # 
10 μl Pipette tips  Different VWR; 613-1068  
100 μl Filter tips Different Biozym; 770100  
100 μl Filter tips  Different Biozym; 770100  
100 μl Pipette tips Different VWR; 613-1066  
100 μl Pipette tips  Different VWR; 613-1066  
1000 μl Filter tips Different Biozym; 770600  
1000 μl Pipette tips Different VWR; 613-1062  
15 ml Falcon tubes  Different Sarstedt; REF 62.554.502  
2 ml Cups  Different Sarstedt; REF 72.695.400  
30 μl Pipette tips  TaqMan  Matrix; 7432  
50 ml Falcon tubes Different Sarstedt; REF 62.547.254  
96-well Microplates Function assays  Greiner bio-one; REF 655101  
Disposable gloves Different Roth; L949.1  
Disposable scalpal Different Feather, No. 11  
Glass cover slips (10 mm Ø)  Immunohistochemistry, flat mounts  VWR; 631-1576  
MicroAmp Optical 384-well Plat  TaqMan  Applied Biosystems; 4326270  
MicroAmp Optical adhesive films  TaqMan  Applied Biosystems; 4311971  
Needle 20G Nr.1  RNA isolation B & D Systems; REF 301300  
Pasteurpipetten  Different VWR; 612-3752  
PCR Cups  PCR  Biozym; 711030 / 711040  
PCR Tube stripes  PCR  Biozym; 711030 / 711040  
Peel-Away® Molds  Embedding  Polysciences, INC.  
Polysine objective slides Different  VWR; 631-1349  
Table 12. Basic materials, use and firm of purchase 
 
2.9 Machines and Software 
Tables 13 and 14: List of machines and software used for experiments 
Machine Use Firm 
3130xl Genetic Analyzer  Sequencing  Applied Biosystems  
7900 HT Fast real time PCR 
System  
TaqMan  Applied Biosystems  
Agilent 2100 Bioanalyzer  RNA Quality Control  Agilent Technologies  
Axioimager Z1 Apotome 
Microscope 
Fluorescent Microscope Zeiss 
Axioimager Z2 Apotome 
Microscope 
Fluorescent Microscope Zeiss 
Axioskop 2 MOT Plus  Fluorescent Microscope Zeiss  
Cold microtome  Cryosections Leica  
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Machine Use Firm 
Dark Hood DH 30/32  Gel documentation  Biostep  
Distille 2012 GFL  Different GFL Burgwedel  
Gel chamber Blue Marine 200  Gel electrophoresis  Blue Power  
Microcentrifuge Different Labnet  
Microscope  DMIL HC kpl. inverse  Different  Leica  
Microscope Leica DM IL  Different Leica  
Microwave Kor-6D07  Different Daewoo  
Multifuge 3L  Different  Heraeus  
Multipipette  TaqMan  Matrix  
NanoDrop  RNA and DNA concentration  PeqLab  
Optomotry© Optokinetic tracking Cerebral Mechanics 
Rotarod (4-40rpm) Rotarod PanLab/Harvard Apparatus 
T3000 Thermocycler  PCR  Whatman Biometra  
Table centrifuge Biofuge fresco  Different Heraeus  
Thermomixer compact 5436  Different Eppendorf  
Thermoprinter P93D  Gel documentation Mitsubishi  
Tissue Lyser  RNA isolation  Qiagen  
Table 13. Machines: use and firm of purchase 
 
Software Use Firm 
   
Agilent 2100 BioAnalyzer  RNA Quality control  Agilent Technologies  
Argus 3.0  Gel documentation  Argus  
Axiovision 4.8 Fluorescent microscope Zeiss  
AxioVision LE 4.5  Fluorescent microscope Zeiss  
Corel Draw X4  Figures Corel  
Edit Seq 5.05  Sequence analysis DNASTAR  
Graphpad prism  Graph plots Graphpad software  
Microsoft Office  Different Microsoft  
RQ Manager 1.2  TaqMan  Applied Biosystems  
SDS 2.3  TaqMan  Applied Biosystems  
SeqMan  Sequence analysis DNASTAR  
Zen 2012 Fluorescent microscope Zeiss  
Table 14. Software: use and firm of purchase 
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3 Methods  
3.1 Mouse Lines and Husbandry 
The animals used in this study were housed in an air‐conditioned environment at 20°C – 22°C and 
were subject to a constant 12 hours light‐dark cycle with free access to water and standard mouse 
diet. Light intensity during light phase was 15 lux. Animal health status was regularly controlled 
and all experimental protocols were approved by the Committee of Animal Health and Care of the 
local government and conformed to international guidelines on the ethical use of animals. All 
efforts were made to minimize the number of animals used and their suffering. The required 
animals were killed, depending on their age, by either direct decapitation or by CO2 asphyxiation 
with subsequent cervical dislocation. Mice were either genotyped using PCR or sequencing. 
 
3.2 Mouse Genotyping 
3.2.1 DNA Extractions 
Mouse tail tips were cut using a sharp blade and the DNA extracted by incubating tails for 20 min 
in 75µl Alkaline Extraction Solution at 95°C, chilling samples on ice and then adding 75µl 
Neutralizing solution.  
3.2.2 Photometric determination of DNA concentration 
A spectrophotometer (Nanodrop ND‐1000) was used to determine the concentration and purity of 
the DNA samples. Absorbance was measured at 260 nm and 280 nm and was calculated using the 
Lambert‐Beer law: E = ε ∙ d ∙ c; with E being the extinction, ε the molar extinction coefficient, d the 
thickness of the sample and c the concentration of the sample. An extinction factor of 1 represents 
50 µg/ml of double-stranded DNA. DNA was considered pure between A260/280 of 1.8 to 2.2 using 
nuclease‐free water as a reference.  
 
3.2.3. DNA amplification with PCR 
Polymerase chain reaction (PCR) is the standard methods used for amplifying  small quantities of 
template DNA within a short time. DNA is mixed with forward and reverse primers, taq-
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polymerase, deoxynucleotide triphosphates (dNTPs) and buffer. During the first step, template 
DNA is denatured at 95°C. Here, the sense and antisense strand are separated from each other. 
During the annealing-phase, primers bind to the single stranded DNA. The annealing temperature 
is dependent on every single pair of oligonucleotide (primer-pair). In the last step, taq-polymerase 
elongates the primers according to the template DNA. The temperature used in the elongation-
phase (72°C) is optimal for the hyperthermophyl bacteria Thermus aquaticus activity, from which 
the taq-polymerase enzyme is isolated. CLN3 DNA were amplified using primer pairs (Table 16 ), 
PCR cocktail mix (Table 15) and PCR program (Table 17).  
 
Mouse line Composition 1x dilution (µl) c (Stocks) c (Dilution) 
Cln3 dNTP-mix 
Primer Forward 
Primer Reverse 
15x Buffer (25mM MgCl2) 
House Taq polymerase 
Nuclease-free water 
gDNA 
4.00 
0.625 
0.625 
2.5 
0.625 
14.625 
2 
1.25mM 
10µM 
10µM 
25mM 
2U/µl 
0.2mM 
0.25µM 
0.25µM 
2mM 
0.05U/µl 
Table 15: PCR solution for Cln3 mouse genotyping 
 
Primer name Sequence Product (bp) Genotyping/Sequencing 
CLN3-WT-F CAGCATCTCCTCAGGGCTA 250 Cln3
+/+
 
CLN3-WT-R CCAACATAGAAAGTAGGGTGTGC  Cln3
+/+
 
CLN3-552 F GAGCTTTGTTCTGGTTGCCTTC 500 Cln3
Δex7-8
 
CLN3-Ex9RA R GCAGTCTCTGCCTCGTTTTCT  Cln3
Δex7-8
 
CLN6 F GGTGCTGGTACCCACTGAAG   
CLN6 R TGCCCTGCTAAGGAACTCAC   
Table 16: Primer pair for Cln3 genotyping and Cln6 sequencing 
 
Mouse line Step Temperature (°C), time Cycle 
Cln3 Pre-denaturing 
Denaturing 
Annealing 
Elongation 
Final Elongation 
95, 2 min 
95, 30 sec 
58, 30 sec 
72, 30 sec 
72, 5 min 
 
 
 
34 
Table 17: PCR program for CLN3 genotyping 
 
3.2.4 DNA amplification for Sequencing 
DNA from CLN6nclf mice was sequenced for an additional cystein insertiona in a six cystein 
sequence found the normal CLN6 amino acid sequence (Table 16, 18). This method first requires 
the amplification of total DNA using a Qiagen Taq Core kit, followed by digestion of DNA to 
separate the strands, then amplification of one of the strands using one of the primer pairs and a 
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fluorescent dye. Once the dye is incorporated into the elongating strand, it causes the polymerase 
to fall off, resulting in different lengths of DNA. Extensive washing steps are done to ensure all the 
unused dye is removed leaving behind pure DNA. DNA is then diluted in formamide, placed in a 96-
well plate and sequenced using the automated capillary electrophoresis  3130xl Genetic Analyzer 
from ABI. Heated formamide causes DNA to denature allowing DNA strands to separate by size and 
migrate down the capillary at different speeds. The analyzer then uses a laser to excite the 
fluorescent material found at the end of the strand causing the DNA to be colored. The computer is 
then able to read the colors and determine the order of the bases in the sample. The Genetic 
Analyzer is operated by the Diagnostic Department at the Institute of Human Genetics at the 
University Clinic Regensburg.  
 
Step Solution composition PCR PCR temperature (°C), time  PCR cycle 
Amplification DNA (25ng/µl)- 2 µl 
10x Buffer- 2.5 µl 
LsgQ- 5 µl 
PF (10µM)-0.5 µl 
PR (10µM)-0.5 µl 
dNTPs-0.5 µl 
Taq-0.25 µl 
H2O-13.75 µl 
Pre-denaturing 
Denaturing 
Annealing 
Elongation 
Final Elongation 
94, 3 min 
94, 30 sec 
58, 30 sec 
72, 1 min 
72, 10 min 
 
 
 
34 
Digestion Exol- 0.1 µl 
AAP (10µM) - 0.25 µl 
H2O- 3.65 µl 
PCR product- 1 µl  
Done in double 
 37, 15 min 
80, 15 min 
 
Cycle 
Sequencing 
5x Buffer- 2 µl 
B.D. 1.1- 0.3 µl  
H2O- 1.7 µl 
Directly into the digestion 
Primer F/R- 1 µl 
Pre-denaturing 
Denaturing 
Annealing 
Elongation 
Final Elongation 
96, 3 min 
96, 30 sec 
55, 30 sec 
60, 3 min 
60, 5 min 
 
Precipitation 
and washing 
NaAC (3M, pH 4.9)- 2 µl 
100% EtOH - 25 µl 
Spin 20 min 4300 U/min 
Dry pellet 
70% EtOH- 100 µl 
Spin 15 min 4300 U/min 
Dry pellet 
HiDi 15 µl 
Plat 
   
Table 18. Method for DNA sequencing 
 
3.2.5 DNA Separation and Analysis 
Quantitative and qualitative DNA analysis were done via agarose gel electrophoresis. Agarose gel 
electrophoresis is a standard method to separate DNA fragments according to their molecular 
weight. The phosphate backbone of nucleic acids is ionized, thus deoxynucleotides are present as 
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anions and migrate from the cathode to the anode in an electric field. Depending on the size of the 
fragments, 1.5 % (w/v) or 2 % (w/v), agarose gel was prepared by dissolving agarose in an 
appropriate amount of TBE buffer and adding a few drops of ethidium bromide. The solution was 
transferred into a gel casting tray and a removable comb was added. DNA samples were mixed 
with 10x DNA loading buffer and 1x TBE buffer. After polymerization the comb was removed and 
the samples were loaded. For size determination, a 1 kb DNA ladder was used. Separation occurred 
at 120 to 150V and took 30 to 45 minutes. ethidium bromide is a DNA intercalating agent allowing 
DNA fragments to be visualized using UV irradiation (dark hood). The agarose gel was documented 
using the Argus 3.0 software. 
 
3.2.6 Sequence Analysis 
Sequences obtained from the Genetic Analyzer were viewed using Sequence Scanner 1.0 and 
compared to a reference sequence using Tools ClustalW2 software.  
 
3.3 Retinal Preparations for Experiments 
3.3.1 Cryo-embedding and Sections 
Enucleated eyes were embedded in TissueTek O.C.T Compound after a short washing step in 1x 
PBS, flash-frozen with dry ice and stored at - 80°C. For permanent fixation of the tissue, the eyes 
were fixed in 4 % PFA for 2 hours and incubated in 18 % sucrose overnight followed by TissueTek 
embedding. 10 µm cryosections were prepared with a CryoMicrotome and mounted onto a 
Polysin-slide. Cryosections were stored at - 80°C for further experiments. 
 
3.3.2 Whole Retinal Flat Mounts 
Eyes were enucleated and fixed in 4 % PFA (4 h/4°C). Using a standard light microscope, a hole 
was made in the cornea and the lens removed. The retina was carefully separated from the RPE 
and stored in 1x PBS for further experiments. 
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3.3.3 Morphometry Experiments 
Before enucleation, eyes were branded on the superiour limbus. Eyes were fixed for 24h in Ito's 
fixative (Karnovsky, 1965) and embedded in Epon. Sections 1 μm in thickness were cut along the 
nasal-temporal plane and stained with fuchsin/methylene blue. Branded enucleated eyes were 
further handled by Prof. Dr. Ernst Tamm's laboratory until eyes were sectioned and ready for 
analysis.  
 
3.4 Morphological and Immunohistological Analyses of Prepared 
Retinae 
3.4.1 Hematoxylin and Eosin Stain 
Hematoxylin and eosin (HE) stain allows for a quick overview of the tissue morphology. This 
method stains the cell bodies blue and the tissue around the cell bodies with a red-ish color. Non-
fixed retinal sections were fixed in 100% ethanol (ETOH) for 20 min at -20°C followed with a 5 min 
washing step in PBS and hematoxylin stain for 5 min. Hematoxylin was washed out with gentle 
running water for 15 min, stained with 1% Eosin Y diluted in water for 3 min , washed for 10 sec in 
water and dehydrated in increasing amount of ETOH (70% 5 sec, 80% 5 sec, 90% 5 sec and 100% 
4 min). Samples were then incubated with 100% Xylol for 3 min and embedded with Xylol-soluble 
Entellan and cover slip.  
 
3.4.2 Immunohistochemical Stain of Retinal Sections 
Cryosections were thawed and air dried at room temperature (RT). Samples which required Iba1 
staining required fixed sections which were first boarded with liquid barrier and further fixed with 
4% PFA for 6 min. After fixation, cryosections were washed 3 times with 1x PBS for 5 minutes 
followed by a 10 min re-hydrating step. Sections were then blocked with BLOTTO 30 min at RT and 
incubated with primary antibody overnight. Samples were then washed with 1x PBS and incubated 
with fluorescently labelled secondary antibody for 1 hour at RT, diluted in 1x PBS (dilutions in 
table 5 and 6 ). During the incubation and all the following steps, the slides were covered to avoid 
bleaching from light. The nuclei were counterstained with 0.1 µg/ml DAPI (10 min/RT). 
Cryosections were embedded with Dako fluorescent mounting medium.  
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3.4.3 Immunohistochemical Stain of Retinal Flat Mounts 
Prepared retinae were incubated with 25% Triton-X/ 25% Tween-20 on a shaker (4°C/ON) to 
ensure full permeability of the tissue. Tissues were then washed extensively with 1x PBS and 
followed the same staining procedure as above. Flat mounts were not counter stained with DAPI. 
Stained flat mounts were cut at four different sections to eliminate the natural rounding of the 
retina and were then embedded with DAKO fluorescent mounting medium. 
 
3.4.4 TUNEL Assay 
Cleavage of genomic DNA during apoptosis causes 'nicks' or breaks in the DNA strand(s). These 
breaks can be visualized by labeling the free 3'-OH end with modified nucleotides in an enzymatic 
reaction (terminal deoxynucleotidyl transferase dUTP nick end labeling, TUNEL). The first step is 
to mark the broken strand with deoxynucleotidyl transferase using terminal transferase (TdT), 
which catalyzes the polymerization of labeled nucleotides to free 3'-OH DNA ends (TUNEL 
reaction). Coupled to an anti-fluorescein antibody, 3'-OH attached fluorescein, also known as the 
peroxidase, can be detected. After subsequent substrate reaction, stained cryosections can be 
analyzed.  
 
Cryosections were fixed in 4% PFA solution (20 min, RT) for 30 min and rehydrated in 1x PBS. 
Endogenous peroxidase activity was saturated with 3% H2O2 solution (10 min / RT), followed by 
tissue permeabilization (2 min, 4°C). The cryosections were treated with 50 µl TUNEL reaction mix 
from the In Situ Cell Death Detection Kit , which was freshly prepared by diluting enzyme solution 
with label solution 1:10 (37°C, 5% CO2, 60 min). As a negative control, label solution without 
enzyme solution was used. For a positive control, cryosections treated with recombinant DNase I 
solution (3,000 U/ul) prior to incubation with TUNEL reaction mix was used (10 min / RT). The 
TUNEL stained DNA fragments were detected using green fluorescence. Nuclei were counter-
stained with DAPI and mounted using DAKO mounting media.  
 
3.4.5 Microscopy 
CLN3 samples and TUNEL stains were viewed using Zeiss Axioskop2 MOT Plus fluorescence 
microscope at 40x magnification. The appropriate filters were used to look at antibodies (488nm), 
auto-fluorescence (594nm) and DAPI stain (405nm). This microscope also allowed for bright field 
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analysis of HE stained tissues. All pictures were processed using Zeiss AxioVision LE 4.5.  CLN6nclf 
retinal sections were studied and imaged using Axioimager Z1 Apotome Microscope at 100x 
magnification. Flat mounts were mounted and view with Axioimager Z2 Apotome Microscope at 
100x magnification using z-stacks of inner and outer plexiform layers as indicated by fluorescent 
sidebars. CLN6nclf retinal sections were further processed using AxioVision LE 4.5 whilst flat 
mounts were processes using Zen 2012. 
 
3.4.6 Retinal Morphometry Analysis 
Eyes prepared for morphometry experiments were viewed using Axioimager Z1 Apotome 
Microscope under bright light settings. The entire retina was imaged using 63x magnification and 
stitched together using the fully licensed AxioVision software.  The length of superior and anterior 
retina were measured using a curved line starting from the optic nerve head (ONH) to the end of 
the retina. The retinal segment was divided into ten equal parts where cross-length measurements 
of the whole retina and photoreceptor were measured. All measurements were exported into 
Microsoft Excel and analyzed.  
 
3.5 Behaviour and Retinal Function Studies 
3.5.1 Optomotry 
The virtual optomotor system allows for rapid quantification of mouse visual acuity as previously 
described (Prusky et al., 2004; Douglas et al., 2005). Freely moving mice were place on a platform 
in the middle of a virtual cylinder made of four computer monitors projecting moving sine wave 
gratings of various spatial frequencies. The mice were visualized using a video camera found on 
the lid of the optomotor system which was connected to computer program OptoMotry. This 
enable the experimenter to track the behavior of the mice without interference. Mice were placed 
on the platform one at a time, and acclimated to their environment by keeping the monitors dim 
and gray. At all times, the mouse's head was tracked using a crosshair cursor superimposed in the 
video image. The coordinates of the crosshair cursor are used as to center the rotation of cylinder 
thus maintaining the virtual walls of the cylinder at a constant distance from the animal and 
effectively maintaining the spatial frequency of the grating. Once the mouse had settled and 
stopped moving, the gray monitors were replaced with a low-spatial-frequency sine wave grating 
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projected on the monitors. If the mouse was able to perceive the grating, it would move its head 
and neck in concert with the rotation. This was repeated a few times with short dim pauses in 
between to ensure accurate readings. The spatial frequency of the grating was increased until the 
mouse no longer responded. The software controlled the speed of rotation, geometry of the 
cylinder, the spatial frequency and contrast of the stimuli and enabled live video feedback of the 
testing arena. The experiment ended when the software had enough data to correctly assess the 
visual acuity of the animal. Experiments lasted between 10-30 minutes. If, during the experiment, 
the mouse fell off the platform, it was simply placed on the platform the experiments continued. 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the Optomotor machine. A. Side view. The mouse is placed on the platform and the 
sine wave grating rotate on the screen surrounding the mouse. B. Top view as seen by video camera. C. The mouse head is the 
center of the rotation of the cylinder. D. When the cylinder is rotating, the mouse tracks the movement with its head and neck. 
These images were adapted from Prusky et al., 2004.  
A B 
C D 
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3.5.1 Rotarod  
Rotarod experiments to assess motor or cognitive difficulties were done on two subsequent days 
on an accelerating Rotarod which accelerated 4-40 rpm in one minute. The speed and time at 
which the mouse fell off the rotarod was recorded. Rotarod apparatus was cleaned after every 
experiment. Experiments were performed three times with 15 minute resting time in between.  
 
3.5.2 Electroretinograms 
All electroretinograms (ERGs) were performed by Prof. Dr. med. Herbert Jägle and Dr. med. 
Cornelia Volz from the University Eye Clinic in Regensburg. A brief method outline was provided 
by Prof. Jägle. Mice were dark adapted for at least 12 hours before the experiments and 
subsequently anesthetized by subcutaneous injection of ketamine and xylazine. Pupils were dilated 
with tropicamide eyedrops. Silver needle electrodes served as reference (fore-head) and ground 
(tail) and gold wire ring electrodes as active electrodes. Corneregel was applied to keep the eye 
hydrated and maintain good electrical contact. ERGs were recorded using a Ganzfeld bowl and an 
amplifier & recording unit. ERGs were recorded from both eyes simultaneously, band-pass filtered 
(1 to 300 Hz) and averaged. Single flash scotopic (dark adapted) responses to a series of ten LED-
flash intensities ranging from -3.5 to 1.0 log cds/m2 with an inter stimulus interval of 2 s up to 20 s 
for the highest intensity were recorded. Response waveforms were analyzed by means of through 
and peak amplitude and implicit time measurement. All analysis and plotting was carried out with 
R 2.14.2 and gplot 0.9.  
 
3.6 RNA Gene Expression Analysis 
Total RNA was isolated from the retina of wild type and mutant mice. All conditions corresponded 
to those recommended for the RNAeasy Kits from Qiagen. All experiments were carried out in 
nuclease free environment and samples were always kept on ice. The yield of the RNA isolation 
depends on the amount of retina removed and the state of the tissue upon removal as well as 
handling during the experiment.  
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3.6.1 RNA Isolation 
RNA isolation from retinal tissue was carried out using the RNeasy Kit from Qiagen. This method 
allows purification of total RNA on hydrophilic silicone gel columns using the appropriate buffer 
systems. First, tissues were homogenized in a buffer containing guanidinium isothiocyanate and 
lysed (RLT buffer). This chaotropic salt denatures all proteins, including RNases and thus 
preserves the RNA from degradation. Tissues were then  homogenized using a tissue lyzer (2 x 30 
sec, 30 Hz). 70% ethanol was added to the supernatant of the homogenate, allowing binding to the 
columns. During subsequent centrifugation (13,000 rpm, 1 min, RT), RNA molecules of 200 
nucleotides bound to the silicon based column whilst the rest of the solution was removed. 
Subsequent washing and centrifugation with RW1 and RPE buffer resulted in pure RNA which was 
eluted with a corresponding volume of nuclease water by centrifugation (13,000 rpm, 1 min, RT). 
RNA was kept at -80 °C until further use 
 
3.6.2 Photometric determination of RNA concentration 
RNA concentrations were measured the same was as DNA samples (see above). A wavelength of 
280 nm provided an indication of possible contamination of the RNA sample with proteins, a 
wavelength of 260 nm corresponds to the absorption maximum of the RNA bases. An extinction 
factor of 1 represents 40 µg/ml RNA. Pure RNA has an absorbance ratio A260/280 of 2.0. 
Nuclease-free water was used as reference. 
 
3.6.3 Reverse Transcription 
Isolated RNA cannot be used as a template in subsequent PCRs, therefore it has to be rewritten 
(reverse transcription) into a complementary DNA strand (cDNA). First-strand complementary 
DNA was carried out using the RevertAidTM H Minus First Strand cDNA Synthesis Kit from 
Fermentas. This includes the RevertAid™ H Minus M-MuLV reverse transcriptase from Moloney 
murine leukemia virus. This enzyme has an optimum temperature of 42-45°C and can synthesis 
cDNA up to 13 kb in length. 
 
The reaction takes place as follows: 
1. 1-3 μg of RNA are diluted into a total volume of 11 μl of nuclease-free water 
2. 1 μl of hexamer primer is added 
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3. The reaction is incubated at 70°C for 5 min 
4. 4 μl of Reaction Buffer + 1 μl of nuclease-free water + 2 μl of 10nM dNTP mix is added 
5. The reaction is incubated at 25°C for 5 min 
6. 1 μl M-MuLV Reverse Transcriptase (200 U/μl) is added 
7. The reaction is incubated at 25°C for 10 min 
8. The reaction is incubated at 42°C for 60 min 
9. The reaction is incubated at 70°C for 10 min (denaturing of the transcriptase) 
10. The reaction is diluted with the appropriate amount of nuclease- free water and store at       
-20°C until needed. 
 
3.6.4 TaqMan technology 
TaqMan PCR uses cyclic amplification of specific PCR product along with fluorescently labeled 
probes (Universal sample Library Probes), which target the desired sequence. The advantages of 
the TaqMan technology are its high sensitivity (<5 ng template sufficient) and specificity, good 
reproducibility and accurate quantification of mRNA. Each probe consists of eight or nine 
nucleotides attached to a fluorophore linked reporter (5 'end) and a quencher (3' end) which is 
complementary to the target sequence. The quencher dye suppresses the fluorescence of the 
reporter by means of fluorescence resonance energy transfer (FRET). As long as the reporter and 
the quencher are in proximity, quenching inhibits any fluorescent signals (Fig. 4). 
 
 
 
 
Figure 4. The principle of TaqMan technology. The probe (in purple) is attached to the fluorophore linked reporter (R) and 
fluorophore quencher (Q). The forward primer is in yellow and the reverse primer in red. Image adapted from 
http://www.asuragen.com/Services/services/gene_expression/ab_taqman.aspx 
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The probes first anneal to a specific region on single-stranded DNA which is amplified by 
designated primers. As the taq polymerase extends the primer and synthesizes nascent DNA, the 5' 
to 3' exonuclease activity of the polymerase cleaves the probe which is annealed to the DNA. This 
cleavage causes the fluorophore to be released from the reporter which breaks its close proximity 
to the quencher molecule allowing fluorescence of the fluorophore. With every PCR cycle, the 
fluorescence intensity increases and is directly dependent on the amount of DNA template present 
in the PCR (Fig. 6 D). The Universal Library sample uses probes made of locked nucleic acids 
(LNA). LNAs are modified nucleotides which have increased affinity for hybridization with 
complementary nucleotides whilst maintaining specificity and melting temperature. The real time 
RT-PCR reactions were performed on 384-well microtiter plates which were scanned after every 
cycle with a laser. The fluorescence intensity was calculated by the SDS 2.3 software program 
connected to the real time PCR system. For the quantification of 50 ng cDNA, a PCR protocol of 40 
cycles was used (denaturation 95 ° C, 40 sec, annealing 60 ° C, 60 sec, elongation, 72 ° C, 2 min). 
The real time RT-PCR analysis was performed in duplicates. PCR solution composition is found in 
Table 19 
 
Compostion 1x dilution (µl) [ ]Stocks [ ]Dilution 
2x TaqMan Gene Expression Mastermix  
Primer (forward)  
Primer (reverse)  
Universal ProbeLibrary Probe  
Nuclease free water 
cDNA (0,02 μg/μl)  
5 
1 
1 
0.125 
0.375 
2.5 
2x 
10 µM 
10 µM 
10 µM 
1x 
1 µM 
1 µM 
0.125 µM 
 
Table 19. 10 µl TaqMan solution 
 
3.6.5 Relative Quantification 
The raw data from the real time RT-PCR experiments can be analyzed using either absolute or 
relative quantification. This work only required relative quantification, which will be described in 
detail. Replication of the cDNA during the PCR reaction increases exponentially. This can be 
represented in a diagram, plotting the fluorescence measured after each cycle to the number of 
cycles. As the amount of fluorescence depends directly on the amount of DNA template initially 
provided, the comparison of gene expression from different samples requires analysis of the CT 
values of each individual reaction. The CT-value (Cycle Threshold) is a threshold value that is 
placed in the linear region of the amplification curve where there is a statistically significant 
increase in gene expression. The CT value is where the threshold line intersects the amplification 
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curve. Therefore, greater initial DNA template have a lower gene expression where as less DNA 
template will have more. Relative quantification is based on a calibrator, a wild type sample, which 
is set to one. In addition, the measured gene expression values are normalized to a reference, or 
housekeeping, gene. A good housekeeping is characterized by a constant gene expression in the 
desired tissue. Normalizing a sample to a reference gene within that sample eliminates human 
experimental error and ensures accurate comparisons of the gene expression with other samples. 
The housekeeping gene used in all experiments was murine ATPase. CT values  and relative 
quantification with the ΔΔCT method was done using the RQ Manager 2.1 software: 
 
1. Calculation of average CT value     --> CT Avg 
2. Normalization to average CT value of reference gene ATPase:  
CT Avg (Gene)- CT Avg (Atpase)     --> ΔCT Avg 
3. In reference to the caibrator 
ΔCT Avg (Probe) - ΔCT Avg (calibrator)    --> ΔΔCT Avg 
4. Relative difference in gene expression    --> 2 -ΔΔCT Avg 
 
3.7 Food Supplementation Study 
Experimental mouse diets were produced at SSNIFF Spezialdiäten GmbH (Soest, Germany) 
consisting of standard mouse diet EF-M (control) supplemented with either 0.6% Curcumin , 0.6% 
Luteolin or 5% DHA. Mice received supplement diets as soon as they were weaned (post natal day 
21-23) and were the fed for 30 weeks. Body weight were measured on a weekly basis for the 
duration of the study.  
 
3.8 Statistics 
real time RT-PCR data from different mouse ages were analyzed using a two-way ANOVA with 
Bonferroni post-test. real time RT-PCR data from the food supplementation study were analyzed 
with a Kruskal-Wallis ANOVA. Rotarod and ERG experiments were analyzed using a one-way 
ANOVA with Bonferroni post-test. P ≤ 0.05 was considered as statistically significant. 
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4. Results  
4.1 Characterization of the Cln3Δex7-8 Retina 
Previous studies done on Cln3Δex7-8 mice showed localized glial activation and inflammation 
preceding and during neuronal degeneration in the brain (Pontikis et al., 2004; Pontikis et al., 
2005). However, little is known about retinal degeneration in this mouse model and whether 
reactive glia and inflammation play a role. One of the objectives of this thesis was to characterize 
the morphological and functional degeneration in the Cln3Δex7-8 retina and determine if Müller cells 
and microglia, in particular, play an active role in degeneration.  
 
4.1.1 Histological Characterization of the Cln3Δex7-8 Retina and 
Immunohistological Evaluation of Müller and Microglia Cells.  
In order to determine the severity and/or presence of retinal degeneration in the Cln3Δex7-8 model, 
mice were studied starting at 18 months of age. This time point would ensure detection of retinal 
degeneration, if present. Retinal sections of 18 month old Cln3Δex7-8 and wild type mice were first 
stained with hemotoxylin-eosin (HE) for morphological comparison (Fig. 6 A ). Both retinas 
appeared to have identical striated retinal morphology with no observable change in the 
photoreceptor or inner and outer nuclear layers (PR, INL and ONL, respectively).  These results 
point towards no obvious morphological degeneration in the Cln3Δex7-8 retina. 
 
The presence and morphology of glial cells was determined as well. Retinal sections of 18 month 
old Cln3Δex7-8 and wild type were stained with GFAP and Iba1, markers for Müller cells and 
microglia, respectively. Cln3Δex7-8 retinas show up-regulated GFAP expression seen as fluorescent 
columns spanning the retina, indicative of reactive Müller cells (Fig. 6 B  ). In contrast, wild type 
retinas showed mostly end-feet signalling in the ganglion cell layer (GCL) with few retinal 
spanning strands normally associated with healthy aging retina.  
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Iba1 staining of microglia revealed morphologically ramified cells in the inner and outer plexiform 
layers (IPL and OPL, respectively) of wild type retinas, where resting retinal microglia are 
normally found (Fig. 6 C). In contrast, Cln3Δex7-8 retinas showed migrating amoeboid microglia with 
little ramifications normally associated active microglia. Auto-fluorescent ceroid lipofuscin deposit 
were detected as bright roundish signals found throughout the Cln3Δex7-8 retina (Fig. 6 D). Wild type 
retinas had little or no storage material in comparison. Microglia were also observed engulfing 
lipofuscin deposits as shown by co-localization of Iba1 signal with auto-fluorescent signal (Fig. 6 
E). Furthermore, flat mount stainings of microglia with Iba1 as a method of better assessing 
microglia morphology (Fig 6 F), showed long ramified microglia in wild type retinas, compared to 
rounder, more alert microglia seen in the Cln3Δex7-8 retinas.  
 
As Müller cells and microglia appear to be active in 18 month old Cln3Δex7-8 retinas, 12 month old 
mutant retinas were also studied (Fig. 7 ). HE stains showed no morphological differences to age-
matched wild type retinas (Fig. 7 A) . GFAP stains showed the presence of active Müller cells (Fig. 7 
B). Sections stained with Iba1 showed ramified microglia in the IPL and OPL as did flat mounts 
(Fig. 7 C, F ). Auto-fluorescent lipofuscin deposits could be seen throughout the retina (Fig. 7 D). 
Figure 5. Histological and immunohistological evaluation of 18 month old Cln3
Δex7-8
 retina, Müller cells and microglia. A. 
Histological comparison of retinal layers in 18 month old (M) wild type (Cln3
+/+
) and Cln3
Δex7-8
 retina with hemotoxylin-eosin (HE) 
stain. B. Immunolabelling of reactive Müller cells with GFAP antibody. C. Immunolabelling of microglia cells with Iba1 antibody. D. 
Auto-fluorescent accumulation of lipofuscin deposits in wild type and Cln3
Δex7-8
 retinas. E. Merged images of Iba1-labeled microglia 
with auto-fluorescent lipofuscin deposits. Arrow indicates co-localization of lipofuscin and microglial cell. E. Iba1-labeled flat-mounts, 
encompassing the plexiform layers, reveal different microglia morphology in wild type and Cln3
Δex7-8
 retinas. PR, photoreceptors; 
ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. 
Scale bar, 50µM.  
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These data indicate microglia activation occurs at a later time point in the Cln3Δex7-8 retina contrary 
to reactive Müller cells which are first seen starting at 6 months (data not shown).  
 
 
 
4.1.2 Functional Characterization of the Cln3Δex7-8 Retina 
To assess changes in visual acuity or retinal function in the Cln3Δex7-8 mouse, optokinetic tracking 
(OKT) and electroretinogram (ERG) measurements were performed. These experiments indicate if 
any kind of retinal degeneration exist in this mouse model which is not obvious using 
morphological studies. Wild type and Cln3Δex7-8 mice were tested at different ages in order to 
temporally assess degeneration.  
 
4.1.2.1 Optomotry Assessment of Visual Acuity 
Visual acuity of Cln3Δex7-8 and wild type mice was studied using OKT measurements in an 
OptoMotry system. OKT is a reliable method for measuring mouse visual acuity by tracking head 
and neck movements in response to gratings projected on a virtual cylinder. Acuity is quantified by 
increasing the spatial frequency of the grating until a tracking response can no longer be elicited. 
OKT measurements of aging Cln3Δex7-8 and age-matched wild type mice were done every two 
Figure 6. Histological and immunohistological evaluation of 12 months old Cln3
Δex7-8
 retina, Müller cells and microglia. A. 
Histological comparison of retinal layers in 12 month old  wild type and Cln3
Δex7-8
 retina with HE stain. B. Immunolabelling of 
reactive Müller cells with GFAP antibody. C. Immunolabelling of microglia cells with Iba1 antibody. D. Auto-fluorescent 
accumulation of lipofuscin deposits in retinas. E. Merged images of Iba1-labeled microglia with auto-fluorescent lipofuscin 
deposits/ E. Iba1-labeled flat-mounts, reveal similar microglia morphology in wild type and Cln3
Δex7-8
 retinas. M, months; HE, 
hemotoxylin-eosin; PR, photoreceptors; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; GCL, ganglion cell layer. Scale bar, 50µM 
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months starting at one month of age until 18 months. (Fig. 8) Wild type mice maintained normal 
OKT thresholds between 0.27 and 0.3 c/d (cycles per degree) at all ages measured. Cln3Δex7-8 mice 
had relatively normal OKT thresholds until 12 months of age, with slight decline starting at nine 
months of age. Past 12 months, OKT thresholds declined faster until 0.4 c/d at 18 months of age, 
indicating almost complete loss of vision. Due to the individual nature of the disease, the standard 
deviation was variable at each measured time point. These results indicate Cln3Δex7-8 mice suffer 
from progressive visual failure which is accelerated past 12 months of age.  
 
 
4.1.2.2 Electroretinograms Measurements of Photoreceptors and Inner 
Retina 
ERG experiments and data analysis were performed by Dr. med Cornelia Volz and Prof Dr. med. 
Herbert Jägle from the University Eye Clinic Regensburg. ERG measurements were performed on 
dark adapted (scoptopic) Cln3Δex7-8 and wild type mice at 6, 12 and 18 months of age (Fig. 9). Rod 
photoreceptor function was measured by the amplitude and implicit time of the leading trough of 
the response wave (a-wave) whereas the inner retinal function was measured by amplitude and 
implicit time of  the positive peak wave (b-wave). At 6 months of age, both wild type and Cln3Δex7-8 
mice had relatively similar a- and b-wave measurements (Fig. 9 A). At 12 months, the a-wave of the 
Cln3Δex7-8 mice had a lower negative drop compared to age-matched wild types, indicating 
decreased photoreceptor function. The b-wave in these mice also had a decreased positive 
amplitude, indicating a degeneration in the inner retinal cells. These differences were most striking 
at high flash intensities. Noteworthy, the decreased measurements of the b-wave was greater than 
the a-wave indicating a larger change in the inner retina compared to photoreceptors. 18 month  
Figure 7. Optokinetic tracking measurement of 
visual acuity using the OptoMotor system in 
Cln3
Δex7-8
  and wild type mice. Changes in optokinetic 
tracking thresholds (cycles/degree) is plotted against 
age in months representing temporal change in visual 
acuity for both wild type and Cln3
Δex7-8 
mice. Mean value 
± SD is shown. n= 5-9 
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Cln3Δex7-8 mice showed further degeneration of the a-wave which became obvious at high flash 
intensity. In contrast, the b-wave of these mice was severely decrease in amplitude at all flash 
intensities, indicating severe degeneration of the inner retinal function. There was no difference in 
implicit time between wild type and Cln3Δex7-8 mice at 6 and 12 months of age (Fig. 9 B). At 18 
month, the Cln3Δex7-8 a-wave implicit time was longer at most flash intensities compared to wild 
type. A graph plotting the b-/a-wave ratio (Fig. 9 C) highlights the lowered b-/a-wave ratio of 
Cln3Δex7-8 mice compared to wild type starting at 12 months of age, indicative of greater 
degeneration in the b-wave compared a-wave.  
 
 
 
Figure 9. Dark adapted (scotopic) ERG response of 
wild type and Cln3
Δex7-8 
mice at 6, 12 and 18 months 
of age. A. Changes in a-wave and b-wave amplitudes 
from low to high flash intensity. B. Implicit time of a-
and b-wave peak response from low to high flash 
intensity. C. b/a-wave amplitude ratio at low to high 
flash intensity. Each symbol represents the mean 
value of minimum three mice ± SD. Data analysis and 
graphs were made by Prof. Dr. Herbert Jägle and are 
used with his consent.  
Figure 8. Dark adapted (scotopic) ERG response 
of wild type and Cln3
Δex7-8 
mice at 6, 12 and 18 
months of age. A-C. Changes in a-wave and b-wave 
amplitudes, implicit response time and b/a-wave 
amplitude ratio from low to high flash intensity. Each 
symbol represents the mean value of minimum three 
mice ± SD. Data analysis and graphs were made by 
Prof. Dr. Herbert Jägle and are used with his consent.  
 44 4. Results 
Interestingly, the aging wild type also show a change in a- and b-wave amplitude as they age. 
Amplitudes decrease by one third from 6 months to 18 months, which is too high to be attributed 
to aging. Upon further speculation, this decrease was attributed to the presence of the Crb1rd8 
mutation (section 4.1.3).  
4.1.3 CRBrd8 Mutation present in the Cln3Δex7-8 and Wild Type Background  
Mattapallil et al. reported the existence of the Crb1rd8 mutation in the C57BL/6N genetic 
background, which could confound retinal function studies in transgenic mouse models 
established on that background (Mattapallil et al., 2012). The Cln3Δex7-8 and corresponding wild 
types were all of the C57BL/6N background and all tested positive for the Crb1rd8 mutation via 
sequencing.  
 
4.1.4 End of Cln3Δex7-8 Study  
Due to the presence of the Crb1rd8 mutation as well as the lack of morphological degeneration and 
early microglia activation, further studies on the Cln3Δex7-8 mouse model were discontinued.  
 
4.2 Characterization of the Cln6nclf Retina 
The second NCL model studied was the Cln6nclf mouse model. Localized microglia and astrocyte 
activation were previously reported in brain studies done on CLN6 mutant sheep model (Oswald et 
al., 2005) and Cln6nclf  mouse model (Bronson et al., 1998; Thelen et al., 2012). Initial studies done 
by Bronson et al. also showed severe retinal degeneration in the Cln6nclf mouse model starting at 
four months with complete loss of retina by nine months (Bronson et al., 1998). The role microglia, 
Müller cells and inflammation play in this degeneration have not previously been studied. Of note, 
Cln6nclf and corresponding wild types were tested negative for Crb1rd8 mutation.  
 
4.2.1 Morphological Characterization of the Cln6nclf Retina 
Temporal retinal degeneration and glial activation in Cln6nclf mice was studied at different ages, 
starting at one month and ending at eight months of age. Histological changes in retina were 
analyzed using a fuchsin/methylene blue dye on 1 μm thick sections (Fig. 10). Retinal sections 
showed a progressive degeneration of all retinal layers in Cln6nclf mice compared to wild-type 
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controls starting at four months (Fig. 10 A). At eight months of age, the photoreceptor cell layer in 
particular was heavily compromised in Cln6nclf retinas with only a few rows of cell nuclei 
remaining.  
 
Next, the glial status in the retina was assessed. Müller glia cells were detected using GFAP as a 
marker (Fig. 10 B). Wild type eight month old mice had some filamentous but mostly end-feet 
GFAP staining associated with normal aging retinas. One month old Cln6nclf mice showed increase 
GFAP staining which became more intense by four months onwards . Increased GFAP expression at 
early ages in Cln6nclf mice indicates reactive Müller cell gliosis as a prominent early event in retinal 
degeneration.  
 
Retinal sections were also stained with the microglia marker Iba1 to assess changes in microglial 
morphology and migration into different layers (Fig. 10 C). Wild type microglial cells were seen in 
a non-alert ramified form in the IPL and OPL. In contrast, one month old Cln6nclf retinas already had 
amoeboid microglia cells with protrusions reaching into the nuclear cell layers. At four, six and 
eight months of age, bloated microglia infiltrating the nuclear layers could be detected, indicating 
fully alert and active microglia. Lipofuscin deposits were seen in photoreceptor and inner-retinal 
layers as early as one month in Cln6nclf mice and increased in number with age (Fig. 10 D). Alert 
phagocytic microglial cells often co-localized with auto-fluorescent lipofuscin deposits suggesting 
phagocytoses of large amounts of auto-fluorescent material (Fig. 10 E, arrowheads). To further 
confirm the morphological transition of ramified microglia cells into large phagocytes, retinal flat-
mounts were stained with Iba1 (Fig 10 F). Retinal flat-mounts from wild-type mice displayed a 
highly ramified microglia network. In contrast, one month old Cln6nclf retinas already showed a 
mixed population of ramified and phagocytic microglia. As the mice aged, the cells became rounder 
in shape with shorter protrusions, indicating a loss of the ramified network structure and an 
alerted state.  
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Figure 9. Histological and immunohistological characterization of wild type and aging Cln6
nclf
 mouse retina. A. Histological 
changes in retina sections from 8 month old wild type mice compared to 1,4,6 and 8 month old Cln6
nclf
 mice using 
fuchsin/methylene (F/M) blue staining. B. Immunolabelling of reactive Müller cells in wild type and aging Cln6
nclf
 retinas using anti-
GFAP antibody. C. Staining of microglial cells in anti-Iba1 antibody. D. Auto-Fluorescent lipofuscin accumulation in wild type and 
Cln6
nclf
 retinas. E. Merged images of anti-Iba immunolabelling with auto-fluorescent lipofuscin deposits. White arrowheads indicate 
co-localization of lipofuscin with microglial cells. F. Anti-Iba1 labelled retinal flat-mount reveal different microglial morphologies in 
wild type and Cln6
nclf 
retinas. The thickness of the flat-mount is indicated on the sides of the images.  OS, outer segments; IS, 
inner segments; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale 
bar, 50 µm. 
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4.2.2 Quantification of Retinal Degeneration 
Histological experiments done on Cln6nclf retinas showed progressive degeneration of cell layers, 
however the rate of cell death and which layers (if any) were more affected was unclear. TUNEL 
assays were performed to assess and quantify in which layers cell death was occurring. Retinal 
morphometry experiments were done to quantify shrinking of total retinal and photoreceptor 
thickness.  
 
4.2.2.1 TUNEL Assay 
TUNEL assays identify which cells are undergoing apoptosis by labeling fragmented DNA strands.  
Cross-sections from six month old wild type as well as one and six month old Cln6nclf retinas 
underwent TUNEL reaction and the labeled cells visualized (Fig. 11). Wild type retinas had only a 
few TUNEL positive cells. One and six month Cln6nclf retinas, showed numerous but equal number 
of TUNEL positive cells located mostly in the ONL. Since Cln6nclf retinal degeneration is progressive, 
cells are constantly undergoing apoptosis, which is why approximately the same number of cells 
can be identified by TUNEL assay at any given time. For this reason, TUNEL positive cells were not 
quantified.  
 
                             
 
 
 
Figure 10. TUNEL stains of Cln6
+/+
 and Cln6
nclf
 retinas. Apoptotic cells in the retina were detected using in situ detection of 
fragmented DNA strands (TUNEL assay). A-C. TUNNEL stain of 6 month old wild type retinas were compared to 1 and 6 month 
old Cln6
nclf
 retinas. PR, photoreceptors; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; GCL, ganglion cell layer. Scale bar, 50µM 
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4.2.2.2 Retinal Morphometry 
As an alternative method of quantifying progressive cell death, retinal morphometric analyses was 
performed. This method allows measurement of total or specific cell layers of the retina making it 
possible to evaluate the progression of cell death as well shrinking of specific layers. Morphometric 
analysis were performed on 1 µm thick retinal sections previously embedded in Epon.  Whole 
retina and photoreceptor membrane thickness of one, four, six and eight month old Cln6nclf and 
wild type mice were measured (Fig 12). Whole retinal measurements indicated changes already 
occurred in the central retina of one month old Cln6nclf mice and this effect steadily increased with 
disease progression throughout the whole retina (Fig. 12 A ). Measuring the Outer and Inner 
Segment (OS and IS, respectively) of the photoreceptors showed a drastic decrease in thickness 
between four and six months, contrary to the steady decrease seen in total retinal thickness (Fig. 
12 B). This marked decrease in photoreceptor membrane thickness coincides with the time point 
when microglia markedly changed their phenotype.        
 
 
 
            
 
 
 
Figure 11. Retinal morphometry measurements of Cln6
+/+
 and Cln6
nclf
 whole retina and photoreceptor membrane. Anterior 
and posterior retinal areas were divided into ten sections using the optic nerve head as a central reference. The thickness of total 
retina and outer/inner segment of photoreceptors was measured and plotted. A. Quantification of whole retinal thickness of Cln6
nclf
 
retinas compared to wild type controls. B. Quantification of photoreceptor layer thickness compared to wild type control. The mean 
value ± SD is plotted. n=4 animals per age group. Cln6
nclf
 measurements were statistically compared to age-matched controls 
using two-way ANOVA followed by Bonferroni post-test. *p < 0.05; **p < 0.01; ***p < 0.001. 
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4.2.3 Behavioural and Functional Characterization of the Cln6nclf Retina 
and Mouse Model 
Functional retinal studies to understand the depth of retinal degeneration in the Cln6nclf model 
were done using OKT and ERGs. Furthermore, possible motor problems exhibited by the Cln6nclf 
mice which could interfere with OKT measurements were also assessed using Rotarod 
measurements.   
 
4.2.3.1 Optokinetic Tracking  
OKT measurements using an OptoMotor system were done on wild type and Cln6nclf mice monthly, 
starting at one month of age and ending at eight months of age (Fig. 13). Wild-type mice had a 
relatively stable maximal OKT threshold at 0.3 c/d. Cln6nclf mice also showed normal OKT 
thresholds up to four months of age which declined slowly, but not significantly. However, starting 
at five months of age, Cln6nclf mice appeared to have a significant and rapid decline in OKT 
thresholds with 0.05 c/d by eight months of age. The large variability of OKT thresholds in older 
animals most likely reflects variable disease progression in Cln6nclf mice.  
 
 
 
4.2.3.2 Rotarod Performance 
To clarify if the progressive decline in visual acuity was indeed due to vision loss and not motor-
neuron deficits, which could also influence OKT readings, rotarod experiments were performed 
Figure 12. Optokinetic tracking measurement of 
aging wild type and Cln6
nclf 
mice. Mouse visual 
acuity was measured via OKT in an OptoMotor 
system. Changes in OKT threshold (cycle/degree) 
is plotted against age in months. Mean value ± SD 
is shown. n= 12 animals per age group. Cln6
nclf
 
measurements were statistically compared to age-
matched controls using  two-way ANOVA followed 
by Bonferroni post-test. ***p <0.001. 
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(Fig. 14). Mice were subjected to rotarod experiments with three trials per day for two consecutive 
days. The performances from both days were compared to determine if mice had improved 
rotarod performance. All mice tested showed a significant improvement on the second day of 
rotarod testing indicating that they had normal learning abilities. However, contrary to four and six 
month old mice which all show approximately the same rate of improvement, eight month old 
Cln6nclf mice had a significantly reduced improvement rate compared to age-matched wild type 
mice. This indicates that older Cln6nclf mice have a reduced cognitive function and/or motor 
impairment. It has been previously reported that these mice start having motor problems at 
approximately eight months of age (Bronson et al., 1998). These results indicate that the decrease 
in OKT measurements from four to six months seen in the Cln6nclf mice is indeed due to a loss of 
visual acuity and is most likely not affected by motor problems. 
 
 
 
4.2.3.3 ERG Measurements of Retinal Function 
ERG experiments were done as mentioned above (section 4.1.2.2) on dark adapted aging CLN6nclf 
and age-matched wild types (Fig. 15). The a-wave amplitude was significantly decreased in one 
month Cln6nclf mice at most flash intensities and progressively decreased until eight months where 
almost no response is recorded (Fig. 15 A). B-wave amplitudes significantly differ from age-
matched controls starting at three months with very little response present at eight months. Wild 
type mice showed a normal mild decrease in both a- and b-wave amplitudes with age. The implicit 
time was not significantly different at most ages compared to controls and was slightly higher in 
eight month old Cln6nclf mice in both the a- and b-wave (Fig. 15 B). Lastly, the b-/a-wave amplitude 
Figure 13. Rotarod performance of wild 
type and Cln6
nclf
 mice aged 4, 6 and 8 
months. Mouse rotarod performance was 
tested three times on two subsequent days 
(Day 1 and 2). The average performance of 
wild type mice on day 2 along with Cln6
nclf
 
performance on both days were normalized to 
wild type performance on day 1. Statistical 
changes in performance from day 1 to 2 for 
each group along with day dependent 
differences between control and Cln6
nclf 
was 
calculated using Kruskal-Wallis ANOVA. n=6-
15 animals per age group. ***p <0.001. 
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ratio was higher for Cln6nclf mice starting at one month of age, indicating an early photoreceptor-
dominated degeneration followed by an inner retinal degeneration (Fig. 15 C). 
 
 
 
 
 
4.2.4 Transcriptional Changes in Stress and Inflammatory Gene Markers 
in the Cln6nclf Retina  
 
Quantitative real-time RT-PCR was used to identify whether progressive retinal degeneration in 
Cln6nclf mice is connected with cell death, stress response and inflammation. Whole retina from 
aging Cln6nclf mice and age-matched wild types (ages one to eight months) were examined for 
transcriptional marker expression changes (Fig 16). Experiments were carried out in duplicates 
and analyzed using ΔΔCT relative quantification.  Age-matched wild types were used as calibrators 
and adenosine triphosphatase (ATPase) as a reference.  
 
First, NCLF mRNA levels were determined to study a potential nonsense-mediated decay of mutant 
mRNA. At all analyzed time points, NCLF transcript levels were significantly reduced in Cln6nclf 
retinas (Fig. 16 A ), indicating that ER-stress pathways could be active in mutant cells. At all ages 
tested, Cln6nclf retinas had half the amount of NCLF mRNA compared to wild type. Next, apoptotic 
and inflammatory markers were studied via CD95 and tumor necrosis factor-alpha (TNFα), 
Figure 14. Dark adapted (scotopic) ERG response amplitudes, implicit times and b/a-wave amplitude ratios of age-
matched wild type and Cln6
nclf
 mice. A-C. Response amplitude of a- and b-wave, implicit response time of a- and b- wave as 
well as b/a-wave ratio were plotted from low to high intensity for 1 and 8 month old wild type, and Cln6
nclf
 mice aged 1 to 8 
months.  Each symbol represents the mean of three animals ± SEM. For the brightest flash intensity, mean amplitude values of 
Cln6
nclf
 mice and age-matched controls were compared with ANOVA. a-wave: 1 month: p=0.0048, 2 months: p=0.0005, 3 to 8 
months: p<0.0001. b-wave: 1 month: p=0.245, 2 months: p=0.059, 3 to 8 months: p<0.0001. Data analysis and graphs were 
made by Prof. Dr. Herbert Jägle and are used with his consent.  
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respectively. CD95  expression (also known as Fas receptor) was increased six to seven fold at one 
and six months in Cln6nclf retinas (Fig. 16 B). At other ages, CD95 expression was on average two 
fold higher in Cln6nclf retinas but was not determined to be significant. TNFα had increased 
expression at all aged test but was significantly increased at eight months (Fig. 16 C). GFAP mRNA 
levels, expressed by reactive Müller cells, were increased five to ten fold in Cln6nclf mice at all ages, 
correlating to the immunohistochemical experiments shown above (Fig. 16 D). Photoreceptor 
stress marker, endothelin 2 (EDN2) was strongly up-regulated in Cln6nclf retinas at all ages, 
indicating a prominent stress response at all ages (Fig 16 E). Next, classical microglia markers: 
CD68, early growth response 1 (EGR1) and complement C1q subunit a (C1qa) were assessed. CD68 
expression was significantly higher in one and six month old Cln6nclf with approximately two-fold 
increased expression at other ages (Fig. 16 F). EGR1 transcript levels were increase four to five fold 
between one and three month of age with expression levels increasing to 12-fold and higher 
starting at four months in Cln6nclf retinas (Fig. 16 G). Finally, C1qa expression levels were 
significantly increased at all ages (Fig. 16 H). These experiments suggest that retinal degeneration 
in Cln6nclf retinas follows a temporally ordered sequence of very early cell stress associated with 
increased immune response. 
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4.3 CLN6nclf Dietary Supplementation Study 
Numerous studies show natural dietary compounds are able to target microglial pathways 
reducing inflammatory processes whilst simultaneously supporting neuronal survival. Based on in 
vivo and in vitro studies which showed significant changes in microglia transcription profile, 
attenuation of activated microglia and decreased neuronal degeneration, three natural compounds 
were selected for this supplementation study: curcumin, luteolin and  docosahexaenoic acid (DHA). 
Cln6nclf mice received standard chow or chow supplemented with 0.6% curcumin, 0.6% luteolin or 
5% DHA for thirty weeks directly after weaning (post natal day 21-23). The study ended when the 
Figure 15. Quantitative real-time RT-PCR expression analysis of Cln6
nclf
 retinas compared to age-matched wild type 
controls. Relative mRNA levels were analyzed for NCLF (A), CD95 (B), TNFα (C), GFAP (D), EDN2 (E), CD68 (F), EGR1 (G) 
and C1Qa (H). mRNA expression was normalized to the reference gene Atp5b and graphed relative to age-matched wild-type (± 
SD). n=7-10 animals per age. Age-matched expression was compared using two-way ANOVA followed by Bonferroni post test. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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mice were seven months old. Mice were weighed weekly to ensure proper and comparable 
development (Fig. 17).   
  
 
 
 
4.3.1 Supplementation effect on Cln6nclf Retinal Histology and Microglia  
Histological comparison of control-fed and supplemented retinas were done as previously 
described (section 4.2.1) (Fig. 18). Supplemented retinas had generally better preserved 
photoreceptor and ONL thickness (Fig. 18 A). The OS of the photoreceptor layers appeared to be 
thicker compared to control retinas, particularly in DHA supplemented retinas. The ONL of control 
retinas comprised of 4 cell layers compared to the 5-6 layers found in curcumin and luteolin 
supplemented retinas and 7-8 layers in DHA supplemented retinas. GFAP staining revealed the 
presence of reactive Müller cells in all retinas (Fig. 18 B). The shape and location of microglia as 
seen by Iba1 staining as well as auto-fluorescent lipofuscin deposits were also comparable in 
control-fed and supplemented mice (Fig. 18 C, D). Retinal flat-mounts stained with Iba1 as a 
method for analyzing microglial morphology revealed different microglial phenotype between 
control and supplemented retinas (Fig. 18 F). Amoeboid microglia with almost not ramifications 
were observed in control retinas, whilst curcumin, luteolin and DHA supplemented retinas had 
highly ramified microglia within an intact network.  
 
Figure 16. Weekly body weight of control-fed and supplemented mice. Wild type body weight is plotted only at 30 weeks. n=12 
animals per group.  
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4.3.2 Retinal Morphometry of Supplemented Retinas 
Histological analysis revealed a better preserved retinal morphology in supplemented retinas 
compared to control. These findings were verified by quantifying the OS and IS length of 
photoreceptors and total retinal thickness using morphometric analysis (Fig. 19). Both curcumin 
and luteolin supplemented retinas had approximately the same total retinal thickness and slightly 
increase photoreceptor thickness which was not significant compared to controls. In contrast, DHA 
Figure 17. Histological and immunohistological comparison of control-fed mice supplemented with 0.6% curcumin, 0.6% 
luteolin and 5% DHA. A. Histological comparison of control animals and supplemented retinas using fuchsin/methylene blue stain. 
B. Immunolabelling of Müller cells with anti-GFAP antibody C. Staining of microglial cells with anti-Iba1 antibody. D. Auto-
fluorescent lipofuscin accumulation in wild type and Cln6
nclf
 retinas. E. Merged images of anti-Iba1 immunolabelling with auto-
fluorescent lipofuscin deposits. F. Anti-Iba1 labeled retinal flat mounts reveal ramified microglia compared to control retinas. The 
thickness of the flat-mount is indicated on the sides of the image. OS, outer segments; IS, inner segments; OPL, outer plexiform 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar, 50 µm. 
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supplemented mice had non-significant increase in total retinal thickness and a significant increase 
in photoreceptor thickness. 
 
 
 
 
 
 
4.3.3 Retinal Function of Supplemented Retinas 
Although supplementation was shown to have some effects on preserving retinal morphology as 
well as attenuating microglial morphology, whether these effects translated to better vision 
remained unclear. Thus, OKT and ERG measurements were performed.  
 
4.3.3.1 OKT Measurements of Supplemented Retinas 
OKT measurements of both control and supplemented Cln6nclf mice were done monthly (Fig. 20).  
As seen previously, non-supplemented Cln6nclf mice had slight decrease in visual acuity up to four 
months of age after which decline became more rapid. By seven months, control mice have an OKT 
threshold of 0.06 c/d.  Mice supplemented with curcumin and DHA both had higher visual acuity 
compared to control mice starting at three months of age onwards. At seven months, curcumin 
supplemented mice had an OKT threshold of 0.156 c/d whereas DHA had an OKT threshold of 
0.139 c/d. Luteolin supplemented mice had uneven OKT measurements until four months of age 
after which thresholds became significantly better than controls. At seven month, mice had an 
average OKT threshold of 0.19 c/d.  
Figure 18. Retinal morphometry measurements of total retina and photoreceptor membrane layer. Anterior and posterior 
retinal areas were divided into ten sections using the optic nerve head as a central reference. The thickness of total retina and 
outer/inner segment of photoreceptors was measured and plotted. A. Quantification of whole retinal thickness of curcumin, luteolin 
and DHA-supplemented versus control retinas. B. Quantification of the photoreceptor layer. Mean value ± SD is plotted. 
Supplemented groups were compared to control using two-way ANOVA followed by Bonferroni post-test. n= 5 animals per group. 
*p< 0.05; **p< 0.01; ***p< 0.001  
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4.3.3.2 ERGs of Supplemented Retinas 
ERGs were done on dark adapted seven month old control and supplemented mice (Fig. 21). A-
wave amplitudes were increased in all supplemented retinas at higher flash intensities compared 
to control. Amplitudes difference were significant in curcumin and DHA supplemented retinas at 
highest flash intensity. B-wave amplitudes were also increased for all supplemented retinas 
compared to control and were also considered significant at highest flash intensity. These data 
indicate a preservation of both the photoreceptor and inner-retinal function. Curcumin and 
luteolin supplemented retinas had similar a- and b-wave implicit time compared to control retinas. 
In contrast, DHA supplemented retinas had shorter implicit time for both a-and b-wave at higher 
flash intensities, which is consist with less severe retinal degeneration. The b/a-wave ratio of both 
luteolin and curcumin supplemented retinas was similar to control retinas. DHA supplemented 
retinas had lower b/a-wave ratio at higher flash intensities, indicating a stronger change in the a-
wave compared to b-wave.  
 
Figure 19. Optokinetic tracking of control 
and supplemented mice. Visual acuity of 
control and supplemented mice was measured 
monthly. Changes in OKT threshold 
(cycle/degree) is plotted against age in months 
Mean value ± SD is shown. n= 12 animals per 
age group. Supplemented measurements 
were statistically compared to controls using  
two-way ANOVA followed by Bonferroni post-
test. *p< 0.05; **p< 0.01; ***p< 0.001 
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4.3.4 Transcriptional changes affected by Supplementation 
Quantitative real-time RT-PCR comparing whole supplemented retinas to non-fed retinas were 
done as previously described (section 4.2.4) (Fig. 22). Seven month wild type retinas were also 
included and compared to non-fed retinas as an additional experimental control. Markers related 
to stress, inflammation and apoptosis were analyzed.  
 
First, mRNA levels of NCLF were analyzed to see if supplementation effected non-sense mediated 
decay (Fig. 22 A). Supplemented retinas had approximately the same level of NCLF expression as 
control retinas. Wild types retinas had approximately two-fold NCLF expression, in concordance to 
experiments done in section 4.2.4. Apoptosis marker, caspase 8 was significantly reduced in DHA 
supplemented and wild type retinas compared to non-fed retinas (Fig. 22 B). A similar profile was 
also seen for CD95 (Fig. 22 C). Reactive Müller cell marker, GFAP, was also significantly reduced in 
DHA supplemented and wild type retinas (Fig. 22 D). This is in contrast to the 
immunohistochemical staining seen above (Fig. 18 B). However, it is possible that the GFAP 
antibody is sensitive enough to detect slightest increase in GFAP expression. END2 expression 
remained the same for supplemented retinas and control with significantly lowered expression in 
wild type retinas (Fig. 22 E).  
Figure 20. Dark adapted ERG response amplitude, implicit time and b/a-wave amplitude ratio of age-matched Cln6
nclf
 
control and supplemented mice. A-C. Response amplitude of a- and b-wave, implicit response time of a- and b- wave as well 
as b/a-wave ratio were plotted from low to high intensity for control and curcumin, luteolin, DHA-supplemented mice at seven 
months of age. Each symbol represents the mean of 6 animals ± SEM. Statistical comparison of supplemented response vs. 
control response was done using two-way ANOVA for the amplitudes of the highest flash intensity. Amplitude: a-wave: p=0.002, 
p= 0.128 and p<0.0001, b-wave: p=0.028, p=0.0147 p=0.009 for curcumin, luteolin and DHA, respectively. Implicit time: a-wave: 
p=0.77, p=0.0983 and p=0.0002, b-wave: p=0.0004, p=0.159 and p<0.0001 for curcumin, luteolin and DHA, respectively. Data 
analysis and graphs were made by Prof. Dr. Herbert Jägle and are used with his consent. 
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Classical microglia marker CD68 was significantly increased in DHA supplemented retinas, as was 
as C1qa (Fig. 22 F, G). As shown before, C1qa levels were significantly decreased in wild type 
retinas. Finally, Tgfβ1 (Transforming growth factor beta), a marker for alternatively activated 
microglia associated with tissue repair and neuroprotection was significantly decreased in wild 
type retinas, as expected, as well as DHA supplemented retinas (Fig. 22 H). These data imply 
curcumin and luteolin had very little effect at the transcriptional level, whereas DHA 
supplementation had positive effects on apoptotic markers and mixed effects on microglia marker 
expression. 
Figure 21. Quantitative real-time RT-PCR expression analysis of curcumin, luteolin, DHA-supplemented retinas compared 
to control. Relative mRNA levels were analyzed for NCLF (A), Caspase 8 (B), CD95 (C), GFAP (D), EDN2 (E), CD68 (F), C1Qa 
(G) and TGFβ (H). Supplemented and wild type mRNA expression was normalized to the reference gene Atp5b and graphed 
relative to control expression (± SD). n= 5 animals per age. Age-matched expression was compared using one-way ANOVA 
followed by Bonferroni post test. *p < 0.05; **p < 0.01; ***p < 0.001. 
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5.1 Comparison of retinal Degeneration in NCL Models 
Loss of vision is an early symptom in most forms of human NCL, indicating the retina is highly 
vulnerable to NCL pathologies (Haltia and Goebel, 2012) However, since patients present vision 
problems long before neurological symptoms emerge, they are often misdiagnosed with 
maculopathies (Birch, 1999) leading to a lack of information of how retinal degeneration in NCL 
progresses or if specific biomarkers are present.  As such, naturally occurring and genetically 
modified animal models of NCL have greatly improved understanding of early disease pathology in 
patients. In many instances, NCL mice recapitulate typical clinical and histopathological features of 
patients including vision loss, neuro-motor deficits and storage of ceroid lipofuscin material in 
lysosomes (Shacka, 2012).  Unfortunately, the little research which has been dedicated to studying 
retinal degeneration in NCL models has led to a large gap in the knowledge of retinal phenotype.  
 
The first part of this thesis focused on characterizing retinal degeneration in two mouse models of 
NCL: Cln3Δex7-8, a model for juvenile NCL, and Cln6nclf, a model for late-infantile NCL. Upon initial 
comparison of both models, it becomes obvious that Cln6nclf mice have a far more severe retinal 
phenotype starting at four months of age compared to the Cln3Δex7-8 model which is relatively 
normal until nine months of age. Histology and morphometry data showed thinning of the nuclear 
layers in Cln6nclf retinas already started at one month of age and progressed until only a few cell 
layers were present in the ONL. This course of retinal degeneration is principally consistent with 
preliminary observations of the initial report describing the nclf phenotype in the Jackson lab 
(Bronson et al., 1998). However, data from this study showed degeneration of the outer retina 
clearly preceded cell death in the inner retina, implicating that photoreceptor cells are very early 
affected during disease progression. In contrast, Cln3Δex7-8 retinas retained cell layers, even at 18 
months of age, with no obvious inner or outer retinal degeneration.  
 
Both retinas did show a large accumulation of auto-fluorescent deposits with age. Accumulation of 
fluorescent storage material has been also reported in the visual cortex and retina of CLN6 mutant 
sheep and other animal models (Oswald et al., 2005; Katz et al., 2011). In mice, retinal auto-
fluorescence has been shown for Ppt1-/- (Lei et al., 2006) and the spontaneous Cln8mnd (motor 
neuron degeneration) mouse model (Seigel et al., 2005). Ppt1-/-, a CLN1 mutant mouse model of 
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infantile NCL, present large amounts of yellow-emitting auto-fluorescent storage bodies from four 
to eight months of age with mild changes in retinal morphology (Lei et al., 2006). In contrast, 
retinal auto-fluorescence in Cln8mnd animals is already evident at birth and photoreceptor loss 
begins at postnatal day 15 (Messer et al., 1993; Seigel et al., 2005). In this regard, Cln8mnd and 
Cln6nclf mice are similar. Accumulation of lipofuscin deposits have also been reported abcr-/- mice, 
a mouse model for Stargardt’s disease, a juvenile form of maculopathy (Weng et al., 1999). In this 
model, the outer segments of the photoreceptor are shortened, as seen in the Cln6nclf retina, 
indicating that accumulation of lipofuscin may cause impairment in the RPE resulting in inability to 
properly maintain photoreceptor membrane homeostasis (Mata et al., 2001).   
 
OKT measurements of Cln3Δex7-8 mice showed slow decline in visual acuity starting at nine months 
with rapid decline occurring past 12 months of age resulting in severe vision impairment at 18 
months. Electroretinogram measurements at six months were normal, at 12 months there was a 
mild decrease in b-wave response, and at 18 months a significant reduction was seen in both a- 
and b-wave (photoreceptors and inner retina, respectively). These data are concurrent with OKT 
measurements. ERG investigations by Staropoli et al. on Cln3Δex7-8 mice up to 16 months of age 
yielded similar results (Staropoli et al., 2012). However, they report virtual no change in a-wave 
response in 16 month old mice. It is possible a marked drop in the a-wave amplitude occurs 
between the 16th and 18th month.  Similar ERG measurements were also reported in Cln3-/- mice 
(Katz et al., 2008).  
 
In contrast, OKT thresholds and ERGs measurements of Cln6nclf mice showed a markedly early 
impaired retinal function. The ERGs indicated an early photoreceptor-dominated degeneration 
followed by inner retinal degeneration. Interestingly, ERG responses were already impaired at one 
month of age, whereas OKT threshold changes were only significant from five months of age 
onwards. Thus, there was a close concordance of early diminished ERG response with retinal 
thinning and quantitative cell loss. Of note, the phenomenon of disconcordant electrophysiological 
and visual behavioral profiles has been recently described in mutant rhodopsin transgenic rats 
(McGill et al., 2012). Similar to the present study, OKT threshold in  rhodopsin transgenic rats did 
not decline until months after significant photoreceptor loss.  
 
The ERG data obtained from Cln6nclf mice is again. similar of the phenotype described in Cln8mnd 
mice (Chang et al., 1994). The amplitudes of the a- and the b-wave rapidly declined with age and 
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the ERG was nearly undetectable at six months in Cln8mnd mice (Chang et al., 1994). The Ppt1-/- 
model shows mild reductions in both a- and b-wave at four months but has dramatic changes in 
ERGs at eight months (Lei et al., 2006). Overall, Cln3Δex7-8 mice have the latest and mildest form of 
retinal degeneration when compared to other NCL models studied. 
 
Comparative analysis of retinal degeneration in the NCL models is, however, confounded with the 
recent discovery of the Crb1rd8 mutation in the C57BL/6N genetic background (Mattapallil et al., 
2012). Cln3Δex7-8 and relevant Cln3+/+ mice were found to be positive for the Crb1rd8 mutation, which 
explains why ERG response amplitudes decreased for Cln3+/+ mice by one/third between 6 and 18 
months. It also makes it difficult to assess how much of the Cln3Δex7-8 retinal degeneration observed 
via OKT and ERGs is really due to the CLN3 mutation. Whether the rd8 mutation influences CLN3 
and to which extent is unknown. Furthermore, ERGs published by Staropoli et al. were also 
conducted on animals with a the C57BL/6N genetic background (Staropoli et al., 2012). Further 
studies on Cln3Δex7-8 mice crossed onto another background, such as C57BL/6J, will elucidate the 
severity of retinal degeneration in these mice. On the other hand, Cln6nclf, Cln8mnd, Ppt1-/- and Cln3-/- 
mice mentioned in the above studies were done on mice with C57BL/6J background, where the rd8 
mutation has not been reported. Furthermore, the Cln6nclf mice used in this study all test negative 
for the mutation. It is safer to assume that retinal phenotypes reported in these mouse models is 
correct. 
 
5.2 Microglia and Müller Cells in NCL Retinal Degeneration 
There is a growing consensus that microglia and astrocytes contribute significantly or even trigger 
apoptosis in several diseases including retinal dystrophies (Schuetz and Thanos, 2004; Maragakis 
and Rothstein, 2006). Microglia and Müller cells are usually the first cells which respond to distress 
signals in the retinal and brain by altering morphology, up/down regulating protein and mRNA 
marker expression in addition to migrating to distressed sites. It is not surprising that activation of 
these cell types have been found in neurodegenerative diseases such as Alzheimer's, multiple 
sclerosis and Parkinson's (Boillee et al., 2006; Kim and Joh, 2006). Furthermore, brain studies on 
NCL animal models as well as patients have also revealed the presence of activated microglia cells 
and astrocytes, often in localized area where significant cell death occurs (Kohlschutter et al., 
1993a; Thelen et al., 2012). However, the presence and contribution of glia cells in NCL retinal 
degeneration is unknown. The second part of this thesis aimed to characterize microglial and 
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Müller cell phenotype in the retina and study whether these cells cause and/or contribute to cell 
death.  
 
5.2.1 Glial Activation in Cln3Δex7-8 Retina 
Cln3Δex7-8 retinas showed up-regulated GFAP expression, a Müller cell marker, as early as six 
months of age. However, microglia morphology was comparable to wild type even at 12 months of 
age and active microglia were seen at 18 months. Since microglia respond to dysfunction of 
photoreceptors or changes in microenvironment, it is possible that these changes are too subtle for 
the microglia to pick up or there are sufficient signals from other cells blocking the microglial 
activation pathway. Since Müller cells span the entire retina and help regulate homeostasis, these 
cells would be more prone to detecting subtle changes in the retina environment. It is also possible 
that the pathways in the Müller cells themselves is affected by the Cln3Δex7-8 mutation causing stress 
and impaired cell function. Intriguingly, Katz et al. only detected CLN3 protein expression in the 
mitochondria of Müller cells and inner retinal cells in wild type mice (Katz et al., 1997). This would 
also explain why the inner retinal cells of Cln3Δex7-8 mice are more affected in the ERGs than 
photoreceptors. Similarly, low grad activation of astrocytes has also been reported in brains of 
both the Cln3-/- and Cln3Δex7-8 mice with little macrophage morphology of microglia. Taken together, 
the Cln3Δex7-8 retinal phenotype is most likely caused by stressed Müller cells and inner retinal cells 
due to dysfunctional mitochondria. It is also likely Müller cells are unable to maintain their 
regulatory functions at later stages in the CLN3 disease resulting in decreased maintenance of 
photoreceptors cells which in turn send out stress signals to the microglia.  
 
The importance astrocytes play in NCL has also been demonstrated in the Ppt1-/- mice. Reactive 
astrocytes were attenuated in these mice by cross breeding with GFAP-/- Vimentin-/- mice resulting 
in an earlier and faster degenerative phenotype with profound neuroinflammatory response 
(Macauley et al., 2011). However, the up-regulation GFAP expression is normally the first 
pathological changes observed in the Ppt1−/− brains (Kielar et al., 2007; Macauley et al., 2009). The 
exact role these glial cells play in NCL pathology is not yet clear. It would be interesting to study if 
Cln3Δex7-8 mice would also have an accelerated phenotype when astrocytes/Müller cells were 
attenuated. This may help elucidate if astrocytes play a more neuroprotective or deleterious role.  
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5.2.2 Glial Activation in Cln6nclf Retina 
Müller cell analysis using GFAP staining and mRNA expression showed early activation already 
present in one month Cln6nclf mice which progressively increased with age. This is considerably 
earlier than GFAP staining of astrocytes in Cln6nclf cerebral cortices, which appear between five to 
six months of age (Bronson et al., 1998; Thelen et al., 2012). Therefore, gliosis associated with 
neuronal degeneration in the Cln6nclf mouse seems to occur in the eye before the brain. Iba1 
detection of microglial cells in retinal sections and flat-mounts demonstrated a mixed population 
of alerted microglia at one month of age which became a homogenous group of amoeboid 
microglia by four months. Amoeboid microglia were seen migrating into nuclear and 
photoreceptor layers coinciding with a loss of microglial network. The presence of amoeboid 
microglia was followed by rapid decrease in OKT measurements, as well as accelerated thinning of 
the photoreceptor layer. This suggests that microglia actively contribute to accelerating retinal 
degeneration once fully active. The presence of active microglia before massive cell death has also 
been reported in the retinoschisis Rs1h-/Y mouse.  In this model, microglia activating transcripts 
precede gene expression patterns related to apoptosis and microglial transformation from 
ramified to an amoeboid phagoctyic morphology coincided with cell death (Gehrig et al., 2007; 
Ebert et al., 2009). Furthermore, highly activated microglia which transformed to a phagocytic 
shape was seen past one year of age in the Cln6nclf mouse brain (Thelen et al., 2012). Similar to 
induction of reactive astrocytes, microglia activation occurs much later in the brain compared to 
retina.  
 
Alerted microglial cells also contained auto-fluorescent granules at all ages examined, which could 
reflect phagocytic processes of dying neurons affected by lysosomal storage of ceroid lipofuscin. In 
Ppt1-/- mice, F4/80 stained mostly microglia in brain regions with prominent neuro-pathological 
changes (Bible et al., 2004). However, storage body accumulation was evenly spread in the brain, 
indicating that lipofuscin deposits per se may not be the trigger for microglial activation (Bible et 
al., 2004). Conversely, in the Cln6nclf  brain, widespread microglial activation closely resembling 
that of lipopigment storage was seen along with localized clusters of activated microglia and 
astrocytes (Thelen et al., 2012). This data suggests that lipofuscin may trigger activation of 
microglia cells, however the presence of localized clusters indicate that other signals are also 
present. These signals may come from stressed neurons and astrocytes/Müller cells.  
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A deeper analysis of inflammation and glial cell activation in the Cln6nclf mouse retina was done via 
temporal mRNA expression profiling. TUNEL assays of Cln6nclf retinas revealed the constant 
presence of apoptosis which is also seen with apoptosis transcript marker CD95. However, highest 
CD95 expression was seen at one and six months, which is also when TUNEL assays were done. At 
other ages, CD95 expression is higher than wild type, but not significantly, indicating the presence 
of constant low level apoptosis. It is likely the number of TUNEL stained cells would  have also 
been lower at other ages tested. Inflammatory marker expression, TNFα, was also increased in 
Cln6nclf mice at all ages, but never significantly, indicating the presence of low-grade inflammation.  
 
Strong and early induction of EDN2 and C1qa were also present in Cln6nclf retinas. EDN2 was 
initially described as a secreted factor of stressed photoreceptors that binds to its receptor EDNRB 
on Müller cells (Rattner and Nathans, 2005). In turn, Müller cells produce leukemia inhibitory 
factor, which triggers release of the survival factor FGF2 in Müller cells and/or photoreceptors to 
protect neurons from further damage (Joly et al., 2008). However, studies on glaucomatous DBA/2J 
show EDN2 is very early up-regulated in retinal microglia and blocking EDN2 with antagonist 
bosentan reduced the incidence of glaucoma development in these mice (Howell et al., 2011). The 
authors speculate since EDN2 is a potent vasoactive peptide, it induces vasoconstriction in the 
ONH and retina during glaucoma causing degeneration.  It is unclear whether EDN2 in the Cln6nclf 
retina is neuroprotective or a microglia-specific signal that triggers photoreceptor degeneration. A 
very similar temporal expression profile was also detected for C1qa. C1qa is subunit of the 
macromolecular C1q complex exclusively synthesized by monocytes, macrophages, and microglial 
cells (Muller et al., 1978; Schafer et al., 2000). As part of the classical complement activation 
pathway, C1qa is a reliable marker of pro-inflammatory non-ramified microglial cells (Farber et al., 
2009). The high expression of C1qa in Cln6nclf retinas at all analyzed time points could suggest that 
alerted microglial cells are present at the very initial stages of NCL disease progression. Since C1qa 
triggers pro-inflammatory cytokine release, phagocytosis and oxidative burst in an autocrine and 
paracrine way (Farber et al., 2009), a constant high level of C1qa in Cln6nclf retinas may reflect 
chronic inflammatory events in NCL. 
 
Activated phagocytic microglia marker CD68 was strongly increased at one and six month in 
Cln6nclf retinas with increased expression at other ages. This expression profile is similar to that of 
CD95, suggesting a co-incident of increase phagocytosis and apoptosis. EGR1 transcript levels were 
also strongly increased in Cln6nclf retinas from four months onwards, with increased expression 
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from one to three months. EGR1 up-regulation is commonly associated with microglial activation 
and their migration into the nuclear layers (Langmann, 2007b; Langmann et al., 2009). 
Interestingly, in the retinal degeneration slow (rds) mouse, the EGR1 response was accompanied 
by induction of neurotrophic factors (Sharma et al., 2012). These authors therefore hypothesized 
that activation of EGR1 and neurotrophic factors could represent a protective immune mechanism 
contributing to the characteristically slow retinal degeneration of rds mice (Sharma et al., 2012). 
The exact function of EGR1 in Cln6nclf microglial cells is unknown and needs further exploration.  
 
Overall, Cln6nclf retinas have an early induction of glial and inflammatory response which coincides 
with accelerated cell death. However, whether microglial activation is the main cause of cell death 
is unclear. Since morphometric and ERG analysis show retinal degeneration already occurs in one 
month old Cln6nclf mice, and no studies have been done prior that that age, it is difficult to assess if 
the retinas of these mice simply never fully develop, or if cell death is occurring independent or 
dependent on microglial activation. Studies on CLN6 sheep have shown activated glial cells present 
in embryo 40 days before animals were born (Oswald et al., 2005). It is possible that enough 
microglia cell are active before the one month time point to cause significant degeneration to the 
retina and that this activation only gets worse as the mice age.   
 
5.3 Immuno-modulation and Neuronal Degeneration Rescue via Dietary 
Supplements 
With the increasing evidence that activated microglial cells release neurotoxic molecules including 
pro-inflammatory cytokines and reactive oxygen species which contribute to neurodegenerative 
processes, heightened effort are being made in finding neuroinflammation-targeting therapeutics. 
This includes screening approved CNS drugs, developing novel synthetic compounds which 
selectively down-regulate neuroinflammation and isolating active compounds from natural 
products (Choi et al., 2011). In fact, several natural compounds exist which can target microglial 
pathways whilst supporting neuronal survival. Curcumin is a herbal medicine which has been used 
for centuries in India and China (Ammon and Wahl, 1991). Curcumin has been shown to reduce 
toxic microglial secretions and protect neurons and photoreceptors (Jin et al., 2007; Jung et al., 
2006; He et al., 2010; Mandal et al., 2009). Luteolin, a flavonoid abundant in leafy greens (Lopez-
Lazaro 2009), has been shown to reduce microglia reactivity in vivo and induce neuroprotective 
phenotype in vitro (Jang et al., 2008; Dirscherl et al., 2012). DHA is highly enriched in the retina 
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and is a precursor for neuroprotectin D1, promoting the survival of photoreceptors and RPE cells 
(Mukherjee et al., 2007). It has also been shown to inhibit microglial synthesis of pro-inflammatory 
cytokines (Antonietta Ajmone-Cat et al., 2012). Furthermore, reports on patients with juvenile NCL 
have found reduced DHA levels in the plasma and cerebral cortex, which may contribute to retinal 
and brain degeneration (Kohlschutter et al., 1993b). On the same note, other hereditary forms of 
retinal degeneration have also been described to have low DHA levels and have used dietary 
supplementation as a therapeutic option (Schaefer et al., 1995; Ebert et al., 2009). 
 
Targeting the immune system in NCL is not a novel idea. Studies done by Groh et al, in which 
lymphocytes were inactivated in Ppt1-/- mice, showed substantial disease attenuation (Groh et al., 
2013). Pharmacological and genetic suppression of the immune system in the Cln3-/- mouse 
resulted in improved motor performance (Seehafer et al., 2011). Since reactive microglia have also 
been identified in CLN3 patients (Haltia, 2003), targeting the immune system and by extension, 
inflammation, has now become an option for therapeutic intervention. The third part of this thesis 
was to select the NCL mouse model with the most prominent glial activation and supplement these 
mice with anti-inflammatory diets in order to reduce glial reactivity and promote neuronal 
survival. As the Cln6nclf mice were found have early Müller and microglial induction which 
correlates with cell death, mice were supplemented with 0.6% curcumin, 0.6% luteolin or 5% DHA 
for thirty weeks directly after weaning.  
 
With all three dietary regimens, OKT measurements were significantly higher compared to non-
supplemented control mice starting at three months for curcumin and DHA and five months for 
luteolin-supplemented mice. Luteolin-supplemented mice had uneven OKT measurements which 
showed initial improvement at three months but drastic decrease in thresholds at four months and 
improvement again thereafter. This puzzling "roller-coaster" effect may be due to an infection 
these particular mice got during the experiment or potential toxic effects of the compound. 
However, no verifications were made. ERG analysis also showed improvements in b-wave for all 
three regimens with DHA having the greatest preservation of the a-wave. The preservation of the 
photoreceptor layer and particularly the outer segments in DHA-treated mice was also highlighted 
in morphometric and histological analyses. A beneficial effect on photoreceptor outer segments 
has also been seen in DHA supplementation of rhodopsin mutant rats, although no alteration in the 
rate of retinal degeneration was detected (Martin et al., 2004). Surprisingly, curcumin did not have 
a larger effect on retinal preservation. Previous studies on rats with light induce retinal 
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degeneration which were supplemented with 0.2% curcumin diet were able to show significant 
decrease in ONL degeneration (Mandal et al., 2009). However, the improvement in ERG 
measurements of these curcumin-supplemented rats is similar to that of the curcumin-
supplemented Cln6nclf mice. Moreover, mice with type 2 diabetes which were given a 2% DHA diet 
also had similar improvements in retinal function as DHA-supplemented Cln6nclf mice (Sapieha et 
al., 2012). 
 
Immunohistochemical analysis of microglia with Iba1 showed mainly ramified cells in all 
supplemented Cln6nclf retinas compared to the amoeboid microglia in controls. However, cross 
sections did show amoeboid microglia migrated into cells layers. Nevertheless, these amoeboid 
microglia did retain extended ramifications, which was not seen in the controls. With these 
somewhat contradictory results, it is important to note that microglia morphology is not always 
equivalent to inflammation state (Graeber et al., 2011). The microglia morphology identified in the 
supplemented Cln6nclf retinas look similar to those found in DHA-supplemented retinoschisis-
deficient mice (Ebert et al., 2009). In this retinal degeneration model, the ramified microglial 
population produced less pro-inflammatory cytokines and the retinal morphology was improved 
upon DHA-treatment (Ebert et al., 2009). Furthermore, BV2 microglia cells treated with LPS 
(lipopolysaccharide) and luteolin also had somewhat amoeboid microglia with long ramified 
protrusions (Dirscherl et al., 2010). These in vitro studies also showed that luteolin was able alter 
microglia transcriptom making it a potent modulator of microglial activation by inducing an anti-
inflammatory, anti-oxidative, neuroprotective phenotype. With this in mind, it is tempting to 
speculate that DHA- and in part curcumin and luteolin-supplemented Cln6nclf retinas display less 
microglial reactivity. Accumulation of lipofuscin deposits for control and supplemented retinas 
appeared to be similar in all cases. 
 
Both luteolin and curcumin did not significantly alter mRNA expression of inflammatory or 
microglial markers. This is quite surprising since in vivo studies of mice supplemented with 
luteolin and curcumin have shown decreased expression of pro-inflammatory cytokines such as IL-
6 and IL-1β (Jang et al., 2008; He et al., 2010). Furthermore, in vitro studies done with both 
compounds on LPS-activated BV2 cells induced the expression of distinct anti-inflammatory gene 
clusters (Dirscherl et al., 2010; Karlstetter et al., 2011).  
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DHA-supplementation also had surprising effects on the retinal mRNA marker expression. Along 
with the expected decrease in apoptosis and inflammatory marker expression of caspase 8 and 
CD95, retinas had an unexpected up-regulation of "classical" activated microglia markers: C1qa, 
CD68 and EGR1 (data not shown). In addition, these eyes also had decreased expression of Tgfβ, a 
marker for 'alternatively' activated microglia associated with neuroprotection. These data suggest 
that DHA-supplementation in Cln6nclf mice pushes for a more activate microglial phenotype, 
however morphology studies suggest the microglia are not completely active. This expression 
profile is in contrast to other studies done concerning microglia and DHA, which report a decrease 
in similar markers (Ebert et al., 2009). Furthermore, studies done on DHA-supplemented type 2 
diabetes mice, showed no change in expression of similar markers, despite improvement in retinal 
function (Sapieha et al., 2012). It is possible that DHA supplementation in CLN6nclf retina push 
microglia to better clear debris and dead cells without letting microglia reach fully alerted states. 
This would also explain how apoptosis markers are significantly decreased in these retinas. 
Decrease in apoptosis can also be attributed to preservation of the photoreceptor outer 
membranes (German et al., 2006). Although, DHA levels in the Cln6nclf mouse have not been 
verified. it is likely these mice, similar to JNCL patients, have low concentrations of DHA in neural 
tissues (Kohlschutter et al., 1993b). 
 
Nonetheless, these studies are not without limitations. Luteolin and curcumin supplementation 
were expected to yield better preservation of the Cln6nclf retina. As both substances are hormetic 
(Mattson and Cheng, 2006; Son et al., 2008), and no previous study has supplemented mice for the 
length of this study, it is possible that curcumin and luteolin had some toxic effects. Furthermore, 
curcumin supplementation studies done on Neimann-Pick disease type C (NPC) mice did lead to 
toxic effects as these mice have innate low levels of cytochrome P450, an important enzyme which 
catalyzes the metabolism of organic products and drugs (this work is not yet published and is in 
review). Curcumin has also been shown to decrease cytochrome P450 levels in rat liver (Oetari et 
al., 1996). This combined effect led to toxic build up of curcumin in NPC mice. Cytochrome P450 
levels have not verified in NCL patients or mice, but since both NPC and NCL are 
neurodegenerative lysosomal storage diseases, it may be an explanation as to why curcumin 
supplementation did not yield better results. Supplementation studies would have to be tested on 
wild type mice and new studies would have to be done with lower doses.  
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mRNA marker expression data may have also been influenced by the low number of mice 
dedicated to those experiment (n=5). Since NCL is an individual disease, it is also expected that 
treatment would have individual results. A larger number of mice would have compensated for 
this variability. Finally, the amount of dietary substance which was reabsorbed and cross the blood 
brain/retinal barrier is unknown. There is evidence that flavonoids Naringenin and Quercetin are 
able to penetrate into the brain (Youdim et al., 2004) but this has not been determined for luteolin. 
Furthermore, curcumin has been detected in the forebrain of mice after systemic injection 
(Purkayastha et al., 2009) and bioactive levels have been shown in the retina after dietary 
supplementation, however curcumin accumulation has not been experimental proven in the retina 
(Mandal et al., 2009). DHA accumulation in the retina has been reported in the rod outer segment 
in mice supplemented with flaxseed oil (Martin et al., 2004). On the other hand, the effect these 
supplements had on the retina could be seen by the positive results in ERG and OKT measurements 
implying that these supplements did have some influence on visual function.  
 
5.4 Perspective  
5.4.1 Cln3 and Cln6: Different but Similar?  
Comparison of retinal degeneration of Cln3Δex7-8 and Cln6nclf were confounded by the presence of 
the Crb1rd8 mutation. Nonetheless, this raises the question of how dis/similar CLN3 and CLN6 are 
to each other, and how similarities and difference might be helpful in better understand NCL 
Although, the CLN6 protein is localized on the ER membrane and CLN3 protein on lysosomal 
membrane, both have been implicated in autophagy mechanisms (Cao et al., 2006; Thelen et al., 
2012). The nclf mutation in CLN6 has been suggested to inhibit fusion between autophagosomes 
and lysosomes whereas the 1-kb mutation in CLN3 delays the maturation of  autophagic vacuoles 
(Cao et al., 2006; Thelen et al., 2012). Moreover, studies undertaken by Cao et al. compared gene 
expression via microarray of primary cerebellar neuronal precursor cells from Cln6nclf and   
Cln3Δex7-8 mice revealed 36 shared probes (out of 1,662 total probes found to be different from wild 
type) with only 8 concordant in their direction of change (Cao et al., 2011). These experiments, as 
well as the ones done in this current study, reveal distinct patho-mechanism exist at least between 
CLN3 and CLN6 disease. This suggests that perhaps treatments which may work for one disease 
would not be so effective in the other. However, better understanding of one of these proteins 
would help elucidate what the function of other NCL proteins may be. Also, the protein expression 
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pattern of CLN6 and most of the other NCLs (such as in Müller cells or certain neurons) would also 
help elucidate which cell types are more affected by the mutation. 
 
Finally, studies in this thesis have shown that the ocular phenotype in NCL is helpful to understand 
molecular mechanisms and could also be useful to develop diagnostic tools for experimental 
therapies. Since vision loss is relatively easier to quantify than motor and behavioral deterioration 
in NCL mouse models, preclinical therapies which ameliorate the retinal phenotype could be an 
effective means to monitor effects on the brain. However, this could only apply to mouse model 
which exhibit a retinal phenotype. 
 
5.4.2 Müller Cells, Microglia and Modulation via Natural Compounds 
In both Cln3Δex7-8 and Cln6nclf retina, Müller cells were found to be reactive. Whether this is because 
of dysfunctional mitochondria, photoreceptor cell death, both or other mechanisms remains to be 
elucidated. Similarly, the balance between neuroprotective and neurodegenerative microglia as 
well as their role in Cln6nclf retinas needs to be further explored. From these studies, the blurred 
lines between what defines "classically" and "alternatively" activated microglia make it difficult to 
assess how much damage microglia cause. This study also highlights the importance of comparing 
microglia morphology and marker expression to get a better understanding of microglial 
reactivity.  
 
As a final point, there is a lot of promise for using natural immuno-modulating compounds as a 
treatment option of neurodegenerative disease. As the knowledge of microglial behavior and 
function in the retina and brain increases, microglia themselves have become a target for 
therapeutic intervention. Clinical trials studying the positive effect of curcumin on Alzheimer's 
disease are underway (clinicaltrials.gov). Furthermore, curcumin is also being used as a non-
invasive biomarker for detecting β-amyloid plaques in the eyes of AD patients via retinal imaging.  
Beneficial effects of reservatrol, ginseng and green tea, amongst a growing number of compounds, 
have all been shown to have positive effects in disease and reduce microglia activating pathways 
(Choi et al., 2011).  
 
Unfortunately there is no widely accepted treatment that can cure, slow down, or stop the 
symptoms of NCL, although phase I clinical trial of neural stem cells for INCL and 
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immunosurpressants for JNCL can slow disease progression for a limited time (clinicaltrials.gov; 
http://www.bdsra.org/ research/Pearce-trial.htm). There is still a lot of work which needs to be 
done in the NCL field towards understanding CLN protein mechanisms, all the key players in NCL 
pathology, and treatment development. Based on the studies done in this thesis, increase in dietary 
anti-inflammatory compounds starting at an early enough time point would help reduce 
inflammation and slow disease progression. However, this type of intervention is by no means a 
cure and would be most beneficial if paired with another treatment option. 
 73 6. Summary 
6. Summary 
Microglia are specialized macrophages of the central nervous system involved in immune 
regulation, tissue development, homeostasis and wound repair. In healthy tissue, microglia are 
found in a ramified state which is tightly controlled by neurons. Upon insult, microglia undergo 
morphological changes, resembling active phagocytic macrophages and are highly motile. In 
neurodegenerative diseases, such are Alzheimer's or multiple sclerosis and in most inherited 
retinal dystrophies, microglia cells are found in a permanent pro-inflammatory active state which 
exacerbates cell death and disease progression. Similarly, astrocytes in the brain or Müller cells in 
the retina, also become reactive in diseased tissue and may contribute to disease progression 
through overshoot release of protective factors such as VEGF (vascular endothelial growth factor), 
massive proliferation and release of inflammatory intermediates which recruit microglia to site of 
injury. Along with active microglia, reactive astrocytes/Müller cells are also found in virtually all 
neurodegenerative and retinal dystrophies.  
 
Microglia and Müller cell status has not been well defined in retinal degeneration of 
neurodegenerative disease neuronal ceroid lipofuscinosis (NCL). The NCLs are early onset 
lysosomal storage disorders characterized by vision loss, mental and motor deficits, and 
spontaneous seizures. Massive accumulation of auto-fluorescent material in neurons lead to 
progressive neuronal degeneration and cell death Furthermore, neuropathological analyses of 
autopsy material from NCL patients and animal models revealed brain atrophy closely associated 
with microglial and astrocyte activity. However, it is unclear whether this phenomenon is mainly 
confined to the brain or also occurs in the retina  
 
Two mouse models of NCL, Cln3Δex7-8  and Cln6nclf, were selected for detailed characterization of 
retinal degeneration with focus on microglia and Müller cell activity. Studies showed that Cln3Δex7-8  
mice had a late onset of retinal degeneration which started at 9 months and progressed until 
severe retinal impairment at 18 months. Reactive Müller cells were present starting at six months 
with no significant microglial activation until late disease stage. Furthermore, degeneration 
originated from inner retinal cells as seen through electroretinograms with little photoreceptor 
death. In contrast, temporal studies on Cln6nclf mice showed an early progressive retinal 
degenerative phenotype which started before one month of age resulting  in loss of vision and 
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retinal function by eight months. Full retinal degeneration was accompanied by reactive Müller 
cells already present at one month of age and fully active microglia at four months. Mixed 
population of ramified and active microglia were seen at one month. Transcript profiling of the 
Cln6ncl mouse retina also showed up-regulated expression of apoptotic, inflammatory and active 
microglia markers.  
 
Based on the strong reactivity of microglia, Cln6nclf mice were supplemented with immuno-
modulatory compounds curcumin, luteolin or DHA in order to ameliorate microgliosis and reduce 
retinal degeneration. Studies showed Cln6nclf mice supplemented with 0.6% curcumin, 0.6% 
luteolin or 5% DHA had improved retinal function, better visual acuity and DHA-supplementation 
had the greatest preservation of photoreceptors. All supplements were able to attenuate microglia 
activation as seen by the presence of microglial ramification and intact network. However, 
curcumin and luteolin supplementation did not have any effect on retinal transcriptom whilst 
DHA-supplementation reduced expression of inflammatory and apoptotic markers. 
 
Taken together, microglial reactivity accompanies disease progression in the Cln6nclf retina but not 
Cln3Δex7-8. Immuno-modulating compounds were able to attenuate disease progression and reactive 
microglia to a certain extent in Cln6nclf mice, indicating modulation of microglial activity could be 
helpful in preserving vision and may ameliorate neuronal degeneration in NCL. Finally, inspection 
of the retinal function may also allow to monitor general disease progression and could be used to 
assess the efficacy of therapeutic interventions for NCL patients. 
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Mikrogliazellen sind spezialisierte Makrophagen des zentralen Nervensystems, die an der 
Immunoregulation, Gewebeentwicklung und Wungheilung beteiligt sind. Im gesunden Gewebe 
liegen Mikrogliazellen in einer verzweigten Form vor, welche von Neuronen kontrolliert wird. 
Nach einer Schädigung ändert sich die Morphologie der Mikrogliazellen und ähnelt dann der von 
aktivierten, phagozytischen Makrophagen. Außerdem werden die Mikroglia dadurch sehr 
beweglich. In neurodegenerativen Erkrankungen, wie Alzheimer oder multiple Sklerose, und in 
den meisten erblichen Netzhautdystrophien befinden sich Mikrogliazellen dauerhaft in diesem 
proinflammatorischen Zustand, welcher den Zelltod und die Progression der Erkrankung 
beschleunigt. In ähnlicher Weise werden Astrozyten im Gehirn oder Müllerzellen in der Netzhaut 
im erkrankten Gewebe aktiviert und können den weiteren Verlauf der Erkrankung negativ 
beeinflussen. Neben aktiven Mikrogliazellen kommen auch reaktive Astrozyten/Müllerzellen in 
praktisch allen neurodegenerativen und retinalen Dystrophien vor. 
 
Die neuronalen Ceroid-Lipofuszinosen (NCL) sind neurodegenerative Erkrankungen, welche mit 
einer Netzhautdegeneration einhergehen. Hier ist der Einfluss von Mikroglia und Müllerzellen 
noch nicht genau bekannt. Die NCL-Erkrankungen sind lysosomale Speicherkrankheiten, die im 
frühen Lebensalter beginnen und durch Sehverlust, mentale und motorische Defizite und spontane 
epileptische Anfälle charakterisiert sind. Eine massive Anreicherung von autofluoreszentem 
Material in den Nervenzellen führt zu fortschreitender Neurodegeneration und zum Zelluntegang. 
Außerdem zeigen neuropathologische Untersuchungen an Autopsiematerial von NCL-Patienten 
und an Tiermodellen eine Hirnatrophie, die eng mit der Aktivität der Mirkoglia und Asztozyten 
assoziiert ist. Es bleibt jedoch unklar, ob sich dieses Phänomen nur im Gehirn abspielt, oder ob es 
auch in der Netzhaut auftritt. 
 
Zwei Mausmodelle für NCL, Cln3Δex7-8 und Cln6nclfb, wurden für eine detaillierte Charakterisierung 
der Netzhautdegeneration untersucht, wobei der Fokus auf die Aktivität der Mikroglia und der 
Müllerzellen gelegt wurde. Studien haben gezeigt, dass die Netzhautdegeneration bei Cln3Δex7-8-
Mäusen erst spät einsetzt. Diese beginnt im neunten Lebensmonat und wird bis zum achtzehnten 
Lebensmonat progressiv schlechter. Das Endstadium der Erkrankung ist schließlich durch eine 
schwere Netzhautschädigung gekennzeichnet. Reaktive Müllerzellen konnten ab dem sechsten 
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Monate identifiziert werden. Eine Aktivierung von Mikrogliazellen hingegen wurde erst in einem 
späten Stadium der Krankheit beobachtet. Des Weiteren begann die Degeneration in den inneren 
Netzhautschichten, wie durch Elektroretinogramme gezeigt werden konnte, wobei die 
Photorezeptoren kaum von dem Zellsterben betroffen waren. Im Gegensatz dazu zeigten Studien 
an Cln6nclf-Mäusen einen frühzeitigen, progressiv degenerativen Phänotyp der Retina, welcher vor 
dem ersten Lebensmonat begann und zum Verlust der Sehkraft und der Netzhautfunktion im 
achten Lebensmonat führte. Während des gesamten Prozesses konnten reaktive Müllerzellen 
beobachtet werden, welche schon im ersten Lebensmonat auftraten. Ferner wurden im ersten 
Monat gemischte Gruppen von verzweigten und aktivierten Mikroglia identifiziert, welche alle 
nach vier Monaten komplett aktiv waren. Expressionsprofile der Netzhaut von Cln6ncl-Mäusen 
zeigten zudem eine erhöhte Expression von apoptotischen, inflammatorischen und aktiven 
Mikrogliamarkern.  
 
Aufgrund der starken Aktivierung der Mikrogliazellen wurden Cln6nclf-Mäuse mit den 
immunmodulatorischen Substanzen Curcumin, Luteolin oder DHA behandelt. Ziel war es, die 
Mikrogliose zu verbessern und die Netzhautdegeneration zu mildern. Studien zeigten, dass 0,6% 
Curcumin, 0,6%Luteolin oder 5% DHA zu einer verbesserten Netzhautfunktion und einer besseren 
Sehschärfe führten. Ferner wurde bei Behandlung mit DHA der größte Erhalt von Photorezeptoren 
beobachtet. Alle Substanzen konnten die Aktivierung der Mikroglia abmildern, was durch die 
Anwesenheit von verzweigten Mikroglia in einem intakten Netzwerk belegt werden konnte. Jedoch 
hatten Curcumin und Luteolin keine Wirkung auf das retinale Expressionsprofil, während DHA die 
Expression von inflammatorischen und apoptotischen Marker reduzierte, aber auch und die 
Expresion der Mikrogliamarker hochregulierte. 
 
Zusammenfassend kann gesagt werden, dass der Phänotyp von Cln6nclf-Mäusen mit einer 
Aktivierung von Mikroglia einhergeht. Diese konnte jedoch nicht bei Cln3Δex7-8-Mäusen beobachtet 
werden. Immunmodulatorische Substanzen waren bei Cln6nclf-Mäusen innerhalb eines gewissen 
Rahmens in der Lage, das Fortschreiten der Erkrankung abzumildern und die Aktivierung der 
Mikroglia einzugrenzen. Dies deutet darauf hin, dass sich die Beeinflussung der Mikrogliaaktivität 
positiv auf den Erhalt der Sehkraft auswirkt und dass die Neurodegeneration bei NCL-Patienten 
abgeschwächt werden kann. Schlussendlich kann die Überprüfung der Netzhautfunktion auch dazu 
dienen, den Fortschritt der Erkrankung zu überwachen und die Wirkung einer Therapie für NCL-
Patienten zu beurteilen. 
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